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Introduzione	
Il	 trattamento	 del	 tromboembolismo	 venoso	 (TEV)	 si	 è	 basato	 per	decenni	 sull’utilizzo	 di	 farmaci	 parenterali	 nella	 fase	 acuta	 (eparina	 non	frazionata,	eparine	a	basso	peso	molecolare,	fondaparinux)		e	di	farmaci	orali	(dicumarolici)	per	la	prevenzione	secondaria	a	medio-lungo	termine.	Questi	ultimi	sono	notevolmente	efficaci	nel	ridurre	il	rischio	di	recidiva	di	TEV,	ma,	a	 causa	 della	 stretta	 finestra	 terapeutica	 e	 della	 variabilità	 farmacocinetica	intra-	 ed	 inter-individuale,	 necessitano	 di	 un	 monitoraggio	 laboratoristico,	allo	scopo	di	minimizzare	sia	il	rischio	di	recidive	trombotiche	che	quello	di	complicanze	emorragiche.1	Negli	 ultimi	 15	 anni	 circa,	 la	 ricerca	 farmacologica	 ha	 portato	 allo	sviluppo	 e	 alla	 sperimentazione	 di	 farmaci	 anticoagulanti	 orali	 diretti	(DOACs),	che	presentano,	rispetto	ai	dicumarolici,	un’azione	più	selettiva,	un	migliore	profilo	di	efficacia/sicurezza	e	caratteristiche	 farmacocinetiche	più	prevedibili,	 tali	da	non	richiedere	uno	stretto	monitoraggio	 laboratoristico.2	Negli	studi	di	fase	III	per	il	trattamento	del	TEV,	i	DOACs	si	sono	dimostrati,	rispetto	 ai	 dicumarolici,	 non	 inferiori	 in	 termini	 di	 efficacia	 e	 hanno	prosentato	 un	 profilo	 di	 rischio	 emorragico	 equivalente	 o	 migliore.3,4,5,6,7	
																																																								
1	Ageno	W,	Gallus	AS,	Wittkowsky	A,	et	al.	Oral	anticoagulant	therapy:	Antithrombotic	Therapy	and	Prevention	of	Thrombosis,	9th	ed:	American	College	of	Chest	Physicians	Evidence-Based	Clinical	Practice	Guidelines.	Chest	2012;141(2	Suppl):e44S-88S	2	Ufer	M.	Comparative	efficacy	and	safety	of	the	novel	oral	anticoagulants	dabigatran,	rivaroxaban	and	apixaban	in	preclinical	and	clinical	development.	Thromb	Haemost	2010;103:572-85	3	The	EINSTEIN	Investigators.	Oral	rivaroxaban	for	symptomatic	venous	thromboembolism.	N	Engl	J	Med	2010;363:2499-2510	4	The	EINSTEIN-PE	Investigators.	Oral	rivaroxaban	for	the	treatment	of	symptomatic	pulmonary	embolism.	N	Engl	J	Med	2012;366:1287-97	
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Pertanto,	 la	 European	 Medicines	 Agency	 (EMA)	 ha	 approvato	 rivaroxaban	(2011),	dabigatran	(2014),	apixaban	ed	edoxoban	(2015)	per	il	 trattamento	del	 TEV	 e	 l’Agenzia	 Italiana	 del	 Farmaco	 (AIFA)	 ne	 ha	 successivamente	autorizzato	 l’utilizzo	 in	 Italia,	 stabilendo	 un	 regime	 di	 rimborsabilità	 per	rivaroxaban	(2013),	apixaban	e	dabigatran	(2015).8	Tra	 gli	 ambiti	 clinici	 che	 possono	 beneficiare	 dall’introduzione	 dei	DOACs,	 vi	 sono	 due	 manifestazioni	 comuni	 del	 TEV,	 	 cioè	 l’embolia	polmonare	 (EP)	 e	 la	 trombosi	 venosa	 profonda	 distale	 isolata	 (TVPDI).	 In	particolare,	per	quanto	riguarda	l’EP,	l’utilizzo	dei	DOACs	puo’	portare,	nella	fase	 acuta,	 ad	 un	miglioramento	 della	 gestione	 dei	 pazienti	 che	 presentano	basso	 rischio	 di	 complicanze	 e,	 nel	 medio-lungo	 termine,	 ad	 una	ottimizzazione	del	profilo	rischio-beneficio	della	 terapia	anticoagulante.	Per	quanto	riguarda	 il	 trattamento	delle	TVPDI,	 le	 cui	evidenze	sono	più	scarse	ed	eterogenee	in	termini	di	scelta	del	farmaco	e	durata	della	terapia,	l’utilizzo	dei	DOACs,	 grazie	 alla	 loro	 semplicità	 di	 uso	 e	 al	 buon	profilo	 di	 sicurezza,	puo’	condurre	ad	una	semplificazione	ed	omogeneità	terapeutica.	Infine,	il	profilo	di	rischio	emorragico	dei	DOACs	puo’	rappresentare	un	vantaggio	rispetto	ai	dicumarolici,	vista	la	dimostrata	riduzione	significativa	
																																																								
5	Agnelli	G,	Buller	HR,	Cohen	A,	et	al;	the	AMPLIFY	Investigators.	Oral	Apixaban	for	the	Treatment	of	Acute	Venous	Thromboembolism.	N	Engl	J	Med	2013;369:799-808	6	Schulman	S,	Kearon	C,	Kakkar	AK,	et	al;	RE-COVER	Study	Group.	Dabigatran	versus	warfarin	in	the	treatment	of	acute	venous	thromboembolism.	N	Engl	J	Med	2009;361:2342-2352	7	Hokusai-VTE	Investigators,	Büller	HR,	Décousus	H,	Grosso	MA,	et	al.	Edoxaban	versus	warfarin	for	the	treatment	of	symptomatic	venous	thromboembolism.	N	Engl	J	Med	2013;369:1406-15	8	Squizzato	A,	Galli	M,	Dentali	F,	et	al.	Outpatient	treatment	and	early	discharge	of	symptomatic	pulmonary	embolism:	a	systematic	review.	Eur	Respir	J	2009;33:1148-55	
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delle	 emorragie	 intracraniche,	 che	 sono	 caratterizzate	 da	 una	 significativa	mortalità	e	morbilità.	
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Obiettivi	
Lo	scopo	del	programma	di	ricerca	era	la	valutazione	dell’impatto	clinico	dei	DOACs,	sotto	il	profilo	di	efficacia	e	sicurezza	in	tre	ambiti	del	TEV:	1)	la	stratificazione	 prognostica	 e	 l’ottimizzazione	 del	 trattamento	 dell’EP,	 	 2)	 il	trattamento	delle	TVPDI	e	3)	la	gestione	delle	complicanze	emorragiche.		In	particolare,	nel	trattamento	dell’EP,	 lo	scopo	del	progetto	era	testare	l’impatto	 dei	 DOACs	 nella	 gestione	 dei	 pazienti	 a	 basso	 rischio	 di	complicanze,	 i	quali	potrebbero	beneficiare	di	una	breve	ospedalizzazione	o	di	un	trattamento	interamente	domiciliare,	grazie	alla	disponibilità	di	farmaci	in	grado	di	 fornire	un’adeguato	 livello	di	anticoagulazione	in	breve	tempo	e	senza	necessità	di	monitoraggio	laboratoristico.		Per	 quanto	 riguarda	 la	 gestione	delle	 TVPDI,	 lo	 scopo	del	 progetto	 era	valutare	 la	 possibilità	 di	 ottimizzare	 e	 standardizzare	 il	 regime	 di	trattamento,	che	attualmente	è	controverso	ed	eterogeneo.			Infine,	 nell’ambito	 delle	 complicanze	 emorragiche,	 il	 progetto	 si	prefiggeva	 di	 valutare	 il	 rischio	 di	 sanguinamento	 e	 la	 sua	 gestione	 nella	pratica	clinica,	dal	momento	che,	rispetto	agli	studi	di	fase	III,	 i	DOACs	sono	utilizzati	in	pazienti	meno	selezionati	e	per	periodi	di	tempo	potenzialmente	più	lunghi.	Durante	 il	 primo	 anno	 di	 svolgimento	 del	 progetto,	 è	 stato	 necessario	apportare	delle	modifiche	al	piano	sperimentale	a	causa	del	ritardo	in	Italia	nell’approvazione	 e	 commercializzazione	 dei	 DOACs	 per	 il	 trattamento	 del	TEV.	 Pertanto,	 sono	 stati	 progettati	 alcuni	 studi	 preliminari/preparatori,	 la	
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cui	 conduzione	 è	 proseguita	 nei	 successivi	 due	 anni.	 Nel	 corso	 del	 II	 anno,	inoltre,	poiché	 il	 regime	di	 rimborsabilità	stabilito	da	AIFA	per	rivaroxaban	(unico	DOAC	 allora	 approvato	 per	 il	 trattamento	 del	 TEV)	 non	 includeva	 il	trattamento	 dell’EP	 e	 della	 TVPDI,	 non	 è	 stato	 possibile	 mantenere,	 come	parte	 centrale	 dei	 progetti,	 gli	 obiettivi	 legati	 ai	 DOACs,	 che	 sono	 stati	pertanto	 inclusi	 come	 obiettivi	 secondari,	 ove	 possibile.	 Per	 le	 medesime	ragioni,	 è	 stato	 giudicato	 opportuno	 ampliare	 i	 progetti	 di	 ricerca	 già	 in	intrapresi.					
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Stratificazione	prognostica	dell’embolia	polmonare	
L’embolia	 polmonare,	 che	 rappresenta	 la	 terza	 causa	 più	 frequente	 di	patologia	 cardiovascolare	 dopo	 le	 sindromi	 coronariche	 acute	 e	 gli	 eventi	cerebrovascolari	acuti,	è	caratterizzata	da	un	ampio	spettro	prognostico,	che	varia	da	una	pronta	risoluzione	dei	sintomi	dopo	alcune	ore	di	 trattamento	alla	morte	improvvisa.	I	 pazienti	 a	 cui	 viene	 diagnosticata	 una	 EP	 vengono	 solitamente	ricoverati	 in	 ospedale	 per	 intraprendere	 il	 trattamento	 anticoagulante	iniziale,	 sebbene	alcuni	di	 loro,	considerati	a	basso	rischio	di	eventi	avversi	(mortalità	 intraospedaliera	 <	 1%),	 possano	 risultare	 idonei	 per	 una	 breve	ospedalizzazione	 (circa	 72	 ore)	 o	 perfino	 per	 una	 terapia	 interamente	domiciliare.9,10,11,12	In	anni	recenti	vi	sono	stati	numerosi	studi	che	si	sono	 focalizzati	sulla	stratificazione	prognostica	dei	pazienti	con	EP	acuta,	allo	scopo	di	adattare	le	strategie	 di	 trattamento	 e	 di	 gestione.	 In	 particolare,	 sono	 stati	 derivati	 e	validati	alcuni	modelli	predittivi	(clinical	prediction	models,	CPM),	tra	cui	vi	
																																																								
9	Konstantinides	SV,	Torbicki	A,	Agnelli	G,	et	al.	2014	ESC	guidelines	on	the	diagnosis	and	management	of	acute	pulmonary	embolism.	Eur	Heart	J	2014;35:3033-69	10	Jaff	MR,	McMurtry	MS,	Archer	SL,	et	al.	Management	of	massive	and	submassive	pulmonary	embolism,	iliofemoral	deep	vein	thrombosis,	and	chronic	thromboembolic	pulmonary	hypertension:	a	scientific	statement	from	the	American	Heart	Association.	Circulation	2011;123:1788-830	11Kearon	C,	Akl	EA,	Comerota	AJ,	Prandoni	P,	et	al.	Antithrombotic	therapy	for	VTE	disease:	antithrombotic	therapy	and	prevention	of	thrombosis,	9th	edition:	American	College	of	Chest	Physicians	evidence-based	clinical	practice	guidelines.	Chest	2012;141	(2	Suppl):e419S-94S	12	Aujesky	D,	Roy	PM,	Verschuren	F,	et	al.	Outpatient	versus	inpatient	treatment	for	patients	with	acute	pulmonary	embolism:	an	international,	open-label,	randomised,	non-inferiority	trial.	Lancet	2011;378:41-8	
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sono	 il	 Pulmonary	 Embolism	 Severity	 Index	 (PESI)13	 e	 la	 sua	 versione	semplificata	 (sPESI)14,	 che	 sono	 risultati	 associati	 ad	 un	 più	 alto	 livello	 di	evidenze	scientifiche15.		Tuttavia,	non	vi	sono	ancora	evidenze	adeguate	sul	 fatto	che	 l’adozione	di	 PESI	 o	 sPESI	 nella	 pratica	 clinica	 cambi	 il	 comportamento	 dei	 medici,	migliori	outcome	clinici	importanti	per	i	pazienti	o	riduca	i	costi16.		Pertanto,	è	stata	pianificato	un	progetto	che	mira	a	valutare	se	la	durata	dell’ospedalizzazione	per	EP	varia	a	seconda	della	stratificazione	prognostica	identificata	da	PESI	e	sPESI	nella	comune	pratica	clinica,	partendo	dall’ipotesi	che	 l’adozione	 di	 questi	 CPM	 possa	 cambiare	 significativamente	 il	comportamento	dei	medici	clinici	nella	gestione	ottimale	dei	pazienti	con	EP.	Il	progetto	comprende	5	fasi:			1.	 Osservazionale:	 acquisizione	 di	 dati	 sulla	 gestione	 dell'EP	 nei	 centri	partecipanti		2.	Educazionale:	presentazione,	ai	 centri	partecipanti,	dei	 risultati	dello	studio	 osservazionale;	 distribuzione	 di	 materiale	 educativo	 riguardante	 la	stratificazione	prognostica	dell’EP;		presentazione	delle	evidenze	provenienti	dai	trial	randomizzati	controllati	(RCT)	dei	DOACs	nel	trattamento	del	TEV	
																																																								
13	Aujesky	D,	Obrosky	DS,	Stone	RA,	et	al.	Derivation	and	validation	of	a	prognostic	model	for	pulmonary	embolism.	Am	J	Respir	Crit	Care	Med	2005;172:1041-6	14	Jimenez	D,	Aujesky	D,	Moores	L,	et	al;	RIETE	Investigators.	Simplification	of	the	pulmonary	embolism	severity	index	for	prognostication	in	patients	with	acute	symptomatic	pulmonary	embolism.	Arch	Intern	Med	2010;	170:	1383–9	15	Squizzato	A,	Donadini	MP,	Galli	L,	et	al.	Prognostic	clinical	prediction	rules	to	identify	a	low-risk	pulmonary	embolism:	a	systematic	review	and	meta-analysis.	J	Thromb	Haemost	2012;10:1276-90	16	McGinn	TG,	Guyatt	GH,	Wyer	PC,	et	al.	Users’̃	guides	to	the	medical	literature:	XXII:	how	to	use	articles	about	clinical	decision	rules.	Evidence-Based	Medicine	Working	Group.	JAMA	2000;	284:	79–84	
Embolia	polmonare	
	
	 8	
3.	Intervento:	assegnazione	randomizzata	dei	medici	all’utilizzo	formale	di	PESI	versus	sola	pratica	clinica	standard,	per	la	stratificazione	prognostica	dei	pazienti	con	EP	4.	Condotta	dello	studio	e	valutazione	degli	outcome	5.	Analisi	dei	dati;	diffusione	dei	risultati;	preparazione	del	manoscritto.	Nella	 fase	di	 intervento	del	progetto,	 al	 fine	di	poter	valutare	 l’impatto	dei	DOACs	 sull’outcome	primario	 (durata	 del	 ricovero	 ospedaliero),	 è	 stato	stabilito	che,	prima	della	randomizzazione,	ciascun	medico	debba	dichiarare	quale	 strategia	 di	 trattamento	 utilizzare	 per	 il	 paziente,	 cioè	 DOACs	 o	trattamento	“tradizionale”	(randomizzazione	stratificata	per	trattamento).	In	tal	modo	sarà	possibile	confrontare	l’outcome	tra	i	seguenti	gruppi:	-		gruppo	1	(PESI)	versus	gruppo	2	(pratica	clinica	standard)	in	pazienti	trattati	con	DOACs		-		gruppo	1	(PESI)	versus	gruppo	2	(pratica	clinica	standard)	in	pazienti	che	ricevono	trattamento	tradizionale	-		gruppo	DOACs	versus	gruppo	trattamento	tradizionale	-	 gruppo	DOACs	versus	 coorti	 della	 fase	osservazionale	 	 (in	 cui	nessun	paziente	ha	ricevuto	DOACs).	La	 prima	 fase	 osservazionale	 del	 progetto	 (Low-Risk	 Pulmonary	Embolism	and	Length	of	Hospital-stay:	the	LORPELHS	study),	comprendente	una	 corte	 “storica”	 (2005-2009)	 e	 una	 coorte	 “attuale”	 di	 pazienti	 (2010-2013),	 viene	 presentata	 di	 seguito	 (manoscritto	 in	 fase	 di	 sottomissione	 a	rivista	scientifica).	
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La	fase	di	 intervento	del	progetto	costituisce	 lo	studio	“Impact	Analysis	of	 Prognostic	 stratification	 for	Pulmonary	 embolism:	 the	 iAPP	 study”,	 il	 cui	protocollo	è	stato	recentemente	approvato	dal	comitato	etico	provinciale	di	Varese	(Ottobre	2015),	ed	è	in	fase	di	partenza,	congiuntamente	agli	8	centri	partecipanti.	
Embolia	polmonare	
	
	 10	
LOW-RISK	PULMONARY	EMBOLISM	AND	LENGTH	OF	HOSPITAL-STAY	IN	
GENERAL	AND	SPECIAL	POPULATIONS	:		THE	LORPELHS	STUDY	
	Marco	P.	Donadini,	Marco	Castellaneta,	Paola	Gnerre,	Micaela	La	Regina,		Luca	Masotti,	Filippo	Pieralli,	Fulvio	Pomero,	Roberta	Re,	Andrea	Gallo,	Francesco	Dentali,	Walter	Ageno,	Alessandro	Squizzato			
Introduction	Pulmonary	 embolism	 (PE)	 is	 the	 third	most	 frequent	 acute	 cardiovascular	disease	after	acute	coronary	syndromes	and	stroke,	with	a	prevalence	of	80	to	 100	 cases/100.000	 persons	 per	 year	 [1].	 PE	 is	 associated	 with	 a	 wide	prognostic	spectrum,	ranging	from	prompt	resolution	of	symptoms	after	few	hours	of	 treatment	 to	sudden	death.	PE	patients	are	commonly	admitted	 to	hospital	for	their	initial	treatment,	though	some	of	them,	who	are	at	low	risk	of	 adverse	 outcomes	 (~1%	 of	 in-hospital	mortality),	may	 be	 suitable	 for	 a	short-hospital	stay	or	even	complete	home-treatment	[2-8].	 In	recent	years,	research	has	focused	on	stratifying	the	risk	of	adverse	outcomes	after	PE,	in	order	 to	 tailor	 treatment	 and	 management	 strategies.	 Although	 some	prognostic	 clinical	 prediction	models	 (CPM)	 have	 been	 adequately	 derived	and	validated,	especially	the	Pulmonary	Embolism	Severity	Index	(PESI)	and	its	simplified	version	(sPESI)	[9-11],	there	is	no	evidence	that	its	use	changes	clinicians	 behavior,	 improves	 PE	 patient	 outcomes	 or	 reduces	 costs	 [12].	Therefore,	 we	 planned	 to	 perform	 an	 impact	 analysis	 study	 to	 evaluate	 if	length	of	hospital-stay	 for	PE	varies	 according	 to	PE	 risk	of	 adverse	events	defined	by	PESI	in	common	clinical	practice.		
Methods	A	 retrospective	 cohort	 study	was	 performed	 on	 consecutive	 adult	 patients	objectively	 diagnosed	 with	 suspected	 or	 unsuspected	 PE	 within	 72	 hours	from	 hospital	 admission.	 The	 study	was	 conducted	 in	 eight	 italian	 internal	
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medicine	 divisions,	 from	2011	 to	 2013.	No	 exclusion	 criteria	were	 applied,	except	for	age	>	18	years.	Suspected	PE	means	that	diagnosis	was	made	by	an	imaging	test	(computed	tomography	 pulmonary	 angiography	 (CTPA),	 pulmonary	 angiography,	 lung	scan,	 compression	 ultrasonography)	 prescribed	 by	 a	 physician	 who	 had	clinical	 suspicion	 of	 PE.	 	 Unsuspected	 PE	 means	 that	 diagnosis	 was	 made	incidentally	by	an	 imaging	test	performed	for	other	clinical	 indications	(e.g.	cancer	staging).	Patients	 were	 identified	 by	 direct	 chart	 review	 or	 by	 searching	 the	administrative	database	of	each	hospital	using	discharges	codes	according	to	the	9th	Clinical	Modification	International	Classification	of	Diseases,	(ICD-9-CM).	 Either	 patients	 with	 primary	 and	 secondary	 diagnosis	 of	 PE	 were	considered.	 Demographic,	 clinical,	 laboratory,	 radiological	 and	 therapeutic	data	were	collected	by	reviewing	clinical	charts;	original	PESI	and	sPESI	were	retrospectively	 calculated.	 We	 anticipated	 a	 higher	 proportion	 of	 missing	data	 for	 PESI	 as	 compared	 to	 sPESI,	 bacause	 of	 the	 higher	 number	 of	variables	(11	and	6,	respectively).	In	addition,	two	centers	could	provide	data	on	sPESI	only	(as	previouly	published).	Patients	were	 classified	 at	 low	 vs.	 high	 risk	 of	 adverse	 events	 according	 to	original	 PESI	 (classes	 I-II	 vs.	 III-V)	 and	 to	 sPESI	 (0	 vs.	 ≥1	 points),	 as	previously	 published.	 	 Furthermore,	 individual	 PESI	 classes	 I	 to	 V	 were	calculated.			The	primary	objective	of	our	study	was	to	retrospectively	evaluate	if	 length	of	 hospital-stay	 for	 PE	 varies	 according	 to	 PE	 risk	 stratification	 of	 adverse	events	defined	by	PESI	and	sPESI,	in	common	clinical	practice.	Secondary	 objectives	 were	 to	 identify	 any	 predictors	 of	 reduced	 length	 of	hospital-stay	 in	 PE	 patients	 and	 to	 compare	 clinical	 characteristics,	prognosis,	and	length	of	hospital-stay	in	PE	special	frail	populations,	such	as	those	with	cancer,	impaired	renal	function	(glomerular	filtration	rate	(GFR)	<	50	mL/min)	and	the	elderly	(>75	years).	
Embolia	polmonare	
	
	 12	
In	addition,	 a	historical	 cohort	was	 included	as	 control	 group,	 consisting	of	patients	diagnosed	with	PE	at	one	center	(Ospedale	di	Circolo,	Varese)	from	2005	 to	2009,	 to	 evaluate	 a	possible	 time-dependent	 trend	of	hospital	 stay	duration	for	PE.		
Statistical	analysis	To	calculate	the	sample	size,	we	considered	that	the	mean	length	of	hospital-stay	for	PE	in	Lombardia	region	is	11.5	days	(data	from	the	Ministry	of	Health	reports,	 2010).	 We	 hypothesized	 that	 the	 distribution	 of	 hospital	 stay	durations	 for	 PE	 would	 have	 a	 standard	 deviation	 of	 4	 days.	 We	 also	hypothesized	that	the	mean	duration	of	hospital	stay	for	low-risk	PE	patients	would	be	shorter	of,	at	minimum,	10%	than	in	high-risk	PE	patients.		Low-risk	PE	patients	are	about	50%	of	 the	entire	PE	population.	Therefore,	with	 alfa	 0.05	 and	 power	 80%,	 we	 calculated	 that	 400	 patients	 were	necessary	 to	 find	 a	 statistically	 significant	 difference	 (p<0.05)	 between	 the	mean	length	of	hospital	stay	of	low-risk	versus	high-risk		groups	of	patients.	Therefore,	 each	of	 the	 eight	participating	 centers	were	 asked	 to	 include	50	patients.	Descriptive	 data	 are	 presented	 as	 means	 with	 standard	 deviation	 (SD)	 or	medians	 with	 interquartile	 range	 (IQR)	 according	 to	 the	 normal	 or	 non-normal	distribution	of	the	variables,	respectively	(Kolmogorov-Smirnov	test).	Student’s	 T-test	 or	 Mann-Withney	 test	 were	 used	 to	 compare	 means	 or	medians	bewtween	two	groups,	respectively.	In	addition,	Kruskal-Wallis	test	was	used	to	compare	medians	between	more	than	two	groups	(i.e.	five	PESI	classes).	A	univariate	logistic	regression	analysis	was	used	to	find	potential	predictors	of	the	length	of	hospital	stay	(considered	as	a	dichotomous	variable	based	on	its	median).	The	dependent	variables	that	resulted	potentially	associated	(p	<	0.15)	 with	 length	 of	 hospital	 stay	 were	 subsequently	 entered	 in	 a	multivariate	model.	
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Anticipating	missing	data	for	PESI,	an	analysis	on	the	best	and	worst	clinical	scenario	 was	 planned,	 inputing	 missing	 data	 on	 PESI	 items	 as	 absence	 or	presence	of	the	condition,	respectively.		
Results	391	patients	with	an	objective	diagnosis	of	PE,	admitted	to	8	italian	internal	medicine	divisions	 from	2011	 to	2013,	were	 included	 in	 the	 study.	Median	age	 was	 77	 years	 (IQR	 69-84),	 165	 patients	 (42.2%)	 were	 males.	 Active	cancer	 were	 present	 in	 87	 patients	 (22.3%).	 Complete	 baseline	characteristics	are	presented	in	Table	1.	Initial	 PE	 treatment	 were	 administered	 according	 to	 local	 practice:	 332	patients	(84.9%)	received	low	molecular	weight	heparin	or	fondaparinux,	33	(8.4%)	 received	 unfractionated	 heparin	 and	 7	 (1.8%)	 received	pharmacological	thrombolysis.	Before	discharge,	247	patients	(63.2%)	were	started	 on	 vitamin	 K	 antagonists.	 No	 patients	 received	 any	 direct	 oral	anticoagulant.		Complete	 data	 on	 sPESI	 were	 available	 for	 380	 of	 391	 patients	 	 from	 8	centers	(97.2%)	and	on	PESI	for	150	of	299	patients		from	6	centers	(50.2%).	According	to	sPESI,	94	patients	(24.7%)	were	classified	at	 low	risk	and	286	(75.3%)	 at	 high	 risk	 of	 adverse	 outcomes.	 Similar	 proportions	 were	identified	by	PESI	(26.7%	and	73.3%,	respectively)	and,	in	particular,	8.7%	of	patients	were	classified	in	class	I,	18%	in	class	II,	26.7%	in	class	III,	15.3%	in	class	IV	and	31.3%	in	class	V.	Overall,	the	median	hospital	stay	was	of	10	days	(IQR	7-14).	The	low	risk	and	high	risk	groups,	as	identified	by	sPESI,	presented	a	median	hospital	stay	of	9	(IQR	7-11)	and	10	(IQR	7-15)	days,	respectively	(P=.027).	The	result	did	not	change	after	excluding	39	patients	(10%)	who	died	in	hospital	(P=.017).	Few	patients	 were	 discharged	 within	 5	 days,	 18	 of	 94	 in	 the	 low	 risk	 	 group	(19.1%)		and	42	of	286	(14.7%)	in	the	high	risk	group	(P=.329).	Similarly,	 the	median	 hospital	 stay	was	 of	 9	 (IQR	 7-13)	 and	 10	 (IQR	 8-15)	days	 in	 the	 low	 risk	 and	 high	 risk	 group	 identified	 by	 PESI,	 respectively	
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(P=.264).	According	to	individual	PESI	classes,	the	median	hospital	stay	was	9	days	for	class	I,	9	for	class	II,	10	for	class	III,	11	for	class	IV,	10	for	class	V	(P=.662).	When	missing	 data	 on	 PESI	were	 analyzed	 according	 to	 the	 best	and	worst	clinical	scenarios,	the	difference	of	median	hospital	stay	between	the	low	risk	and.	high	risk	group	did	not	change	(9	vs.	10	days,	P=.008,	and		9	vs.	10	days,	P=.019,	respectively).	Possible	 predictors	 of	 prolonged	 hospital	 stay	 were	 analyzed	 by	 logistic	regression.	 In	 the	 final	 multivariate	 model,	 no	 variables	 were	 significantly	associated	with	 the	 length	of	hospital	 stay,	with	 the	exceptions	of	 impaired	renal	failure	(GFR,	<	50	mL/min)	and	anemia	(haemoglobin	<	10	g/dL)	that	were	 only	 marginally	 associated	 with	 a	 prolonged	 hospitalization	 (P=.057	and	.064,	respectively).		
Secondary	analysis	Special	populations	245	patients	(62.7%)	aged	≥	75	years	were	included	in	the	study.	Compared	to	 the	 entire	 study	 population,	 a	 lower	 proportion	 of	 these	 patients	 was	classified	by	sPESI	at	 low	risk	(11.3%)	and	a	higher	proportion	at	high	risk	(88.7%)	of	adverse	outcome.	The	overall	median	hospital	stay	was	of	10	days	(IQR	7-15),	similar	to	that	of	the	entire	study	population.	However,	there	was	a	 non-statistically	 significant	 difference	 of	 2	 days	 between	 the	 low	 risk	 (9	days,	 IQR	7-11)	and	high	risk	group	(11	days,	 IQR	7-15)	(P=.091),	 that	was	slightly	larger	compared	to	the	entire	population	(1	day).		Similar	 results	 were	 found	 in	 80	 patients	 with	 impaired	 renal	 function	(calculated	 GFR	 <	 50	mL/min),	 who	were	 hospitalized	 for	 a	median	 of	 11	days	 (IQR	7.5-15.5),	with	a	difference	of	2.5	days	between	 the	 low	risk	 (10	days,	 IQR	 7.5-14)	 and	 high	 risk	 group	 (12.5	 days,	 IQR	 7.75-15.5),	 although	not	statistically	significant	(P=.466).	Finally,	87	patients	with	active	cancere	were	 included	 in	 the	study,	none	of	them	 classified	 at	 low	 risk	 using	 sPESI,	 by	 definition.	 The	median	 hospital	stay	was	10	days	(IQR	6-15),	similar	to	the	entire	study	population.	
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Control	group	The	 results	 of	 a	 cohort	 of	 363	patients	 diagnosed	with	PE	within	72	hours	from	 hospital	 admission	 from	 2005	 to	 2009	 at	 one	 center	 (Ospedale	 di	Circolo,	Varese),	were	 compared	 to	 the	present	 study.	The	median	hospital	stay	 of	 the	 entire	 2005-2009	 population	 was	 12	 days	 (IQR	 9-17),	 and	 in	particular	it	was	11	days	(IQR	8-15)	in	the	low	risk	group	and	12	days	(IQR	9-19)	in	the	high	risk	group	(P=.068).	In	relative	terms,	this	non	statistically	signifcant	difference	of	1	day	between	the	low	risk	and	high	risk	is	similar	to	that	 found	 in	 the	 present	 (2011-2013)	 study.	 However,	 in	 absolute	 terms,	there	is	a	difference	of	2	days	in	the	overall	median	hospital	stay	between	the	two	entire	cohorts	(10	days	in	the	2011-2013	cohort		vs.	12	days	in	the	2005-2009	cohort)	and	between	the	groups	at	low	risk	(9	vs.	11)	and	high	risk	(10	vs	 12	 days),	 that	 may	 indicate	 a	 time-dependent	 trend	 towards	 shorter	hospital	stay	for	PE.		Table	1.	Baseline	characteristics	 	Patients,	n	 391	Age,	ys	(mean,	SD)	 74.6	(13.8)	Sex,	male	(%)	 165	(42.2)	Asymptomatic	PE	 57	(14.6%)	Proximal	DVT,	n	(%)	Isolated	distal	DVT,	n	(%)	 128	(32.7%)	30	(7.7%)	Simplified	PESI,		n	(%)	
• Low	risk	
• High	risk	 	94	(24.7%)	286	(75.3%)	PESI,	n	(%)	•	class	I	•	class	II	•	class	III	•	class	IV	•	class	V	•	Low	risk	(I-II)	•	High	risk	(III-V)	
	13	(8.7%)	27	(18%)	40	(26.7%)	23	(15.3%)	47	(31.3%)	40	(26.7%)	110	(73.3%)	
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Table	2.	Results	
Prognostic	stratification	 Length	of	hospital	stay,	days,	median	(IQR)	 P	Simplified	PESI,		n	(%)	
• Low	risk	
• High	risk	 	9	(7-11)	10	(7-15)	 .027	PESI,	n	(%)	•	class	I	•	class	II	•	class	III	•	class	IV	•	class	V	•	Low	risk	(I-II)	•	High	risk	(III-V)	
	9	(5.5-12.5)	9	(7-15)	10	(8-13.75)	11	(8-14)	10	(7-15)	9	(7-13)	10	(8-15)	
	.662					.264		
	
Discussion	The	 study	 shows	 that,	 in	 the	 clinical	 context	of	 internal	medicine	divisions,	the	 duration	 of	 hospital	 stay	 for	 PE	 was	 generally	 long	 (median	 10	 days)		both	 in	 frail	 patients	 (eg	 patients	 with	 cancer,	 impaired	 renal	 function,	advanced	age)	and	in	the	general	population.	When	patients	were	classified	at	low	or	high	risk	of	adverse	outcomes,	by	retrospectively	applying	sPESI,	a	statistically	 significant	 difference	 of	 1	 day	 was	 found	 between	 the	 two	groups.	However,	this	difference	is	not	clinically	meaningful.		Therefore,	 in	 clinical	 practice,	 the	 clinical	 judgment	 on	 prognostic	stratification	of	PE	does	not	seem	to	be	a	major	determinant	of	the	duration	of	 hospital	 stay.	 It	 is	 also	 possible	 that	 the	 clinical	 feeling	 alone	 (i.e.	 not	supported	by	validated	tools	that	formally	provide	a	prognostic	stratification	such	 as	 PESI)	 is	 not	 sufficient	 per	 se	 to	 take	 adequately	 informed	 clinical	decisions	on	the	best	timing	of	discharge.	Indeed,	compared	to	the	available	evidence	and	current	clinical	guidelines,	a	hospital	stay	of	9	days	for	patients	at	 low	 risk	 of	 adverse	 outcome,	 found	 in	 this	 study,	 is	 significantly	 longer	than	72	hours	or	5	days	suggested	by	recent	evidence.		Large	and	consistent	evidence	shows	that	patients	identified	to	be	at	low	risk	by	PESI	have	a	 short-term	risk	of	mortality	of	 less	 than	1%.	Therefore,	 the	
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adoption	 of	 PESI	 in	 clinical	 practice	 may	 assisit	 clinicians	 in	 correctly	identifying	this	group	of	patients,	who	may	benefit	from	a	short	hospital	stay.	Moreover,	the	calculation	of	PESI	is	simple,	especially	in	its	simplified	version	(being	 represented	 by	 commonly	 available	 anamnestic	 variables	 and	 vital	parameters,	that	are	already	part	of	the	initial	evaluation	of	a	patient).		Nonetheless,	 in	 addition	 to	 the	 clinical	 data	 included	 in	 PESI,	 several	 other	variables	 may	 play	 an	 important	 role	 in	 the	 physicians’	 decision	 on	 the	duration	of	hospital	stay.	First,	PE	still	represents	a	potentially	lethal	disease,	thus	 making	 physicians	 worried	 about	 an	 early	 discharge.	 In	 addition,	 the	treatment	 of	 PE	 may	 be	 dangerous	 in	 itself,	 bacause	 of	 potentially	 severe	bleeding	 or	 treatment	 failure,	 thus	 making	 a	 prolonged	 hospitalization	reassuring	for	physicians.		Second,	anticoagulant	therapy	may	not	be	easy	to	take	by	some	patients.	 Indeed,	heparin	 injections,	especially	 if	administered	more	than	once	daily,	may	represent	an	obstacle	to	early	discharge	in	many	contexts	 (unwilling	 patients,	 absence	 of	 dedicated	 nurses	 or	 familiar	support).	 In	 addition,	 VKA	 overalapping	 and	 INR	 monitoring	 may	 further	complicate	 the	 initial	 therapy,	 thus	 increasing	 the	physicians’	perception	of	potentially	 high	 risk	 of	 under	 or	 over	 anticoagulation	 in	 the	 crucial	 early	treatment	 phase.	 	 Third,	 an	 early	 discharge	 should	 rely	 on	 adequate	 home	circumstances,	 such	 as	 the	 availability	 of	 anticoagulation	 clinics	 or	 trained	family	doctors	for	early	follow-up,	an	adequated	distance	from	the	hospital	in	case	of	therapy	complications	or	suspected	recurrent	VTE,	in	additon	to	the	already	mentioned	dedicated	nurses	and	adequate	family	support	for	elderly	or	frail		patients.	The	study,	 therefore,	seems	to	suggest	 that	PESI	may	have	a	 limited	 impact	on	 the	management	 of	 PE.	 However,	 the	 retrospective	 design	 of	 the	 study	does	 not	 allow	 definitive	 conclusions	 on	 the	 impact	 of	 PESI	 in	 clinical	practice,	 but	 the	 results	 provide	 preliminary	 data	 on	 the	 usefulness	 of	adopting	 this	 prognostic	 prodiction	model.	 Indeed,	 even	 if	 PESI	 is	 a	widely	validated	model,	its	adoption	in	clinical	practice	needs	to	be	tested	by	impact	analyses,	 i.e.	 to	 demonstrate	 a	 change	 in	 clinician	 behavior	 with	 beneficial	
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consequences,	 such	 as	 taking	 better	 decisions	 and/or	 	 improving	 patients’	outcomes	(eg	quality	of	life)	and/or	reducing	costs.	This	objectives	should	be	evaluated	 prospectively	 in	 studies	 that	 ideally	 randomize	 physicians	 or	medical	divisions	to	adopt	or	not	PESI	in	the	clinical	decision	making	process.		Moreover,	 addressing	 variables	 related	 to	 physicians’	 and	 patients’	 values	and	 to	 the	 health	 system	organization	 could	have	 a	 relevant	 impact	 on	 the	length	of	hospital	stay	for	PE.	For	istance,	the	time	dependent	trend	that	was	found	towards	a	reduction	of	hospital	stay	(12	days	in	2005-2009	versus	10	days	in	2011-2013)	may	reflect	an	impact	of	the	increasing	evidence	on	the	safety	of	early	discharge	of	PE	patients	at	low	risk	of	mortality,	as	suggested	in	clinical	practice	guidelines	from	2011.	Our	 study	 has	 limitations.	 First,	 the	 retrospective	 design	 of	 the	 study	 was	associated	 with	 missing	 data,	 especially	 for	 PESI	 (11	 items).	 A	 secondary	analysis	 was	 performed	 inputing	 missing	 data	 according	 to	 the	 best	 and	worst	clinical	scenario	and	the	results	was	comparable	to	those	of	the	main	analysis.	Moreover,	the	calculation	of	the	simplified	version	of	PESI	(6	items)	was	available	for	more	than	97%	of	patients.	Second,	some	variables	potentially	impacting	on	the	timing	of	discharge	were	not	 collected,	 such	 as	 the	 time	 to	 reach	 a	 therapeutic	 INR.	 However,	 in	addition	 to	PESI,	 several	other	 clinical,	 laboratoristic	 and	 imaging	variables	that	 could	 be	 potentially	 associated	 with	 the	 length	 of	 hospital	 stay	 were	colelcted	 and	 tested	 in	 a	 logistic	 regression	 analysis,	 without	 finding	 any	statistical	 significant	 association	 in	 the	 multivariate	 model.	 This	 finding	reflects	 also	 the	 complexity	 of	 the	 prognostic	 reasoning,	 that	 encompasses	several	variables	of	different	fields.	Third,	the	number	of	patients	from	each	centers	were	not	equally	distributed,	thus	potentially	increasing	or	reducing	the	impact	of	some	centers.	However,	this	 difference	 only	 reflects	 the	 size	 of	 the	 participating	 centers	 and	 it	 is	unlikely	to	introduce	a	significant	bias,	since	patients	were	consecutive,	thus	increasing	the	internal	validity	of	the	results.		
Embolia	polmonare	
	
	 19	
Last,	the	centers	were	located	in	northern	Italy,	thus	potentially	limiting	the	generalizability	of	the	results.	However,	the	multicenter	design	of	the	study,	including	eight	centers	from	four	different	regions,	may	increase	the	external	validity	of	the	results.	In	 conclusion,	 in	 this	 study	 the	 median	 length	 of	 hospital	 stay	 for	 PE	 was	generally	long.	The	difference	of	one	day	between	the	low-risk	and	high-risk	groups	 of	 patients	 according	 to	 sPESI	 was	 statistically,	 but	 not	 clinically	significant.	 Whether	 adopting	 PESI/sPESI	 in	 clinical	 practice	 can	 assist	clinicians	to	take	better	decisions	about	the	optimal	duration	of	hospital	stay	needs	to	be	prospectively	evaluated.		
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Trattamento	delle	trombosi	venose	profonde	distali		
Le	 trombosi	 venose	profonde	distali	 isolate	 (TVPDI)	 interessano	una	 o	più	vene	della	gamba,	senza	coinvolgimento	della	vena	poplitea,	 includendo	pertanto	le	vene	assiali	(vene	tibiali	anteriori,	tibiali	posteriori	e	peroneali)	e	le	vene	muscolari	del	polpaccio	(vene	gemellari	mediali,	gemellari	 laterali	e	soleali).		Le	 TVPDI	 costituiscono	 una	 manifestazione	 comune	 del	 TEV,	rappresentando	 circa	 il	 20%	 e	 il	 50%	 di	 tutti	 gli	 eventi	 	 tromboembolici	venosi17.	Nonostante	 ciò,	 i	 dati	 disponibili	 sulla	 storia	naturale	delle	TVPDI	sono	 molto	 eterogenei.	 Le	 TVPDI	 possono	 estendersi	 al	 distretto	 venoso	prossimale	e/o	embolizzare	alle	arterie	polmonari,	possono	andare	incontro	a	 risoluzione	 spontanea	 oppure	 si	 può	 avere	 una	 ricanalizzazione	 del	 vaso	interessato	nell’arco	di	qualche	settimana	o	mese18.	Tradizionalmente,	le	TVPDI	vengono	considerate	una	patologia	benigna,	soprattuto	 se	 confrontante	 con	 le	 trombosi	 venose	 profonde	 (TVP)	prossimali,	 sebbene	 fino	 al	 20-25%	 possa	 estendersi	 al	 distretto	prossimale19.	In	aggiunta,	un’EP	silente	è	presente	nel	13%-33%	dei	pazienti	con	diagnosi	di	TVPDI20.	
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Trombosi	venose	profonde	distali		
	
	 22	
Per	quanto	riguarda	il	rischio	di	recidiva	tromboembolica,	l’ottenimento	di	informazioni	adeguate	è	ostacolato	dall’eterogeneità	degli	studi	in	termini	di	 tipo	 di	 trattamento	 iniziale,	 durata	 dell’anticoagulazione,	 durata	 del	follow-up	 e	 definizione	 degli	 outcome.	 Per	 esempio,	 stati	 riportati	 tassi	 di	recidiva	 di	 circa	 il	 2-3%	 dopo	 un	 anno	 dalla	 diagnosi	 di	 TVPDI	 in	 alcuni	studi21,22,	mentre	 tassi	 significativamente	 più	 alti,	 fino	 al	 9-19%	dopo	 circa	due	anni,	sono	stati	riportati	in	altri	studi23,24.		Vi	 è	 ancora	 incertezza	 sulla	necessità	di	 trattare	 tutti	 i	 casi	 di	 TVPDI	 e	sulla	 durata	 ottimale	 del	 trattamento	 anticoagulante.	 Le	 linee	 guida	 sulla	terapia	 antitrombotica	 del	 TEV	 dell’American	 College	 of	 Chest	 Physicians	suggeriscono	di	trattare	solo	pazienti	selezionati,	cioè	coloro	che	presentano	sintomi	severi	o	fattori	di	rischio	per	estensione	della	trombosi25.	Per	questi	pazienti	 è	 suggerito	un	 trattamento	anticogulante	della	durata	di	minimo	3	mesi,	 come	 per	 i	 pazienti	 con	 TVP	 prossimale.25	 Tuttavia,	 queste	raccomandazioni	sono	deboli,	basate	su	un	basso	 livello	di	evidenze.	 Infatti,	un	ciclo	di	terapia	anticoagulante	più	breve	(4-6	settimane)	è	stato	utilizzato	
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in	diversi	studi22,26,27,	con	risultati	favorevoli	quanto	confrontato	con	cicli	più	lunghiErrore.	Il	segnalibro	non	è	definito.,26,28.	In	 considerazione	 di	 questa	 eterogeneità	 di	 informazioni,	 è	 stato	pianificato	uno	studio	di	coorte,	con	lo	scopo	di	valutare	il	rischio	di	recidiva	tromboembolica	 venosa	 in	 pazienti	 consecutivi	 con	 una	 diagnosi	 di	 TVPDI	sintomatica,	 che	 hanno	 ricevuto	 terapia	 eparinica	 a	 basso	 peso	molecolare	(EBPM)	 secondo	 il	 protocollo	 terapeutico	 locale	 (1	 settimana	 a	 dosaggio	terapeutico,	seguita	da	3-5	settimane	a	dosaggio	dimezzato).				Lo	 studio	 viene	 presentato	 di	 seguito	 (manoscritto	 in	 fase	 di	sottomissione	a	rivista	scientifica).									
																																																								
26	Ferrara	F,	Meli	F,	Amato	C,	Cospite	V,	Raimondi	F,	Novo	G,	Novo	S.	Optimal	duration	of	treatment	in	surgical	patients	with	calf	vein	thrombosis	involving	one	or	more	veins.	Angiology	2006;	57:	418-23	27	Parisi	R,	Visonà	A,	Camporese	G,	et	al.	Isolated	distal	deep	vein	thrombosis:	efficacy	and	safety	of	a	protocol	treatment.	Treatment	of	Isolated	calf	Thrombosis	(TICT)	Study.	Int	Angiol	2009;	28:	68-72	28	Sartori	M,	Cosmi	B,	Legnani	C,	et	al.	Two	years	outcome	of	isolated	distal	deep	vein	thrombosis.	Thromb	Res	2014;134:36-40	
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LONG-TERM	RECURRENCE	OF	VENOUS	THROMBOEMBOLISM	AFTER	
TREATED	SYMPTOMATIC	ISOLATED	DISTAL	DEEP	VEIN	THROMBOSIS:		
A	RETROSPECTIVE	COHORT	STUDY		Marco	P	Donadini,	Francesco	Dentali,	Samuela	Pegoraro,	Fulvio	Pomero,	Chiara	Brignone,	Luigina	Guasti,	Luigi	Steidl,	Walter	Ageno	
	
Introduction			Isolated	distal	deep	vein	 thrombosis	 (IDDVT)	represents	a	 common	clinical	manifestation	of	venous	thromboembolism	(VTE),	ranging	from	20	to	50%	of	all	VTE	events	[1].	Despite	this	high	incidence,	scant	and	heterogeneous	data	are	 available	 on	 the	 clinical	 history	 of	 IDDVT	 	 [2,3].	 	 IDDVT	 is	 commonly	considered	 a	 benign	 disease,	 in	 particular	 when	 compared	 with	 proximal	DVT,	although	up	to	20-25%	of	 IDDVTs	extend	to	the	proximal	vein	system	[4,5],	in	particular	when	IDDVT	is	unprovoked	[6],	bilateral	[7],	involves	more	than	one	distal	vein	[8],	presents	 large	 thrombosed	vessels	diameter	 [9],	or	when	it	is	associated	with	active	cancer	[10].	Moreover,	the	results	of	a	recent	systematic	 review	 of	 the	 literature	 show	 that	 13%	 to	 33%	 of	 IDDVT	 are	associated	with	 asymptomatic	 pulmonary	 embolism	 (PE)	 at	 onset,	most	 of	which	represented	by	micro-emboli	[11].	Information	 on	 the	 recurrence	 rates	 of	 the	 disease	 are	 hampered	 by	 the	heterogeneity	 among	 studies	 in	 terms	 of	 initial	 treatment,	 duration	 of	anticoagulation,	 duration	 of	 follow-up	 and	 definition	 of	 outcomes.	 A	recurrence	rate	of	2-3%	after	1	year	was	reported	 in	some	studies	 [12,13],	whereas	a	higher	rate	up	to	9-19%	after	about	2	years	was	reported	in	other	studies	[7,9].		There	 is	still	uncertainty	on	the	need	to	treat	all	cases	of	 IDDVT	and	on	the	optimal	duration	of	anticoagulation	[14].	Current	guidelines	suggest	that	only	selected	patients	diagnosed	with	 IDDVT	(ie	 those	with	severe	symptoms	or	risk	 factors	 for	 extension)	 should	 be	 treated,	 and	 that	 in	 these	 patients	
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anticoagulation	should	be	given	for	a	minimum	of	3	months,	as	 for	patients	with	 proximal	 DVT	 [15].	 However,	 these	 recommendations	 are	 weak	 and	mainly	 based	 on	 low	 level	 of	 evidence.	 Indeed,	 a	 shorter	 course	 of	anticoagulation	(i.e.	4	to	6	weeks)	was	used	in	several	studies	[6,8,12,16-18]	and	favourable	results	were	found	when	compared	to	longer	durations	[8,12,	18].	Given	the	paucity	and	the	heterogeneity	of	available	information,	we	decided	to	 perform	 a	 retrospective	 cohort	 study	 aimed	 at	 evaluating	 the	 long-term	risk	 of	 recurrent	 VTE	 in	 consecutive	 patients	 diagnosed	with	 symptomatic	IDDVT,	 who	 received	 anticoagulant	 therapy	 according	 to	 a	 center-based	protocol,	and	were	followed-up	for	at	least	2	years.	
	
Methods		The	study	was	conducted	on	consecutive	patients	objectively	diagnosed	with	symptomatic	 IDDVT	 between	 January	 2004	 and	 December	 2011	 at	 the	Thrombosis	and	Haemostasis	Center	of	 the	university	hospital	of	Varese,	 in	Italy,	 which	 serves	 as	 a	 tertiary	 referral	 center	 for	 the	 diagnosis	 and	treatment	of	patients	with	venous	thromboembolism.		Patients	were	eligible	if	aged	≥	18	years	and	if	no	concomitant	proximal	DVT	and/or	 PE	 were	 diagnosed.	 Asymptomatic	 PE	 was	 not	 systematically	searched.	Based	on	an	internal	protocol	active	from	2004,	all	patients	presenting	with	suspected	 symptomatic	 IDDVT	were	 evaluated	by	means	of	 bilateral	whole	leg	compression	ultrasound,	performed	by	trained	physicians,	according	the	method	 of	 Schellong	 [19].	 All	 the	 examinations	 were	 registered	 on	 a	computerized	database,	and	patients	diagnosed	with	IDDVT	were	scheduled	for	regular	follow-up	visits	for	up	to	6	months	after	the	diagnosis.	According	to	the	protocol,	all	patients	were	initially	treated	with	low	molecular	weight	heparin	(LMWH)	for	4	to	6	weeks	(1	week	full	dose,	followed	by	3	to	5	weeks	half	dose).		In	case	of	contraindications	to	anticoagulation	(eg	active	bleeding,	high	risk	of	bleeding,	platelet	count	<	30.000/mm3,	known	allergy	to	LMWH	
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or	 severe	 renal	 failure),	 treatment	and	 follow-up	strategies	were	 left	 to	 the	treating	physician,	who	decided	on	 a	 case	by	 case	basis,	 and	patients	were	not	excluded	from	the	study.		Baseline	 characteristics	 were	 routinely	 collected	 on	 demographic	characteristics,	 risk	 factors	 for	 VTE,	 site	 and	 extension	 of	 IDDVT,	 type	 and	duration	of	anticoagulant	treatment	and	were	retrospectively	retrieved	from	the	 center	 electronic	 database.	 Follow-up	 information	was	 retrieved	 for	 all	scheduled	 follow-up	 visits	 until	 6	 months	 from	 the	 index	 event	 and	integrated	 by	 	 a	 telephone	 contact	with	 all	 patients,	 up	 to	 at	 least	 2	 years	from	the	diagnosis	of	IDDVT.		The	 primary	 study	 outcome	was	 the	 composite	 of	 objectively	 documented	recurrent	 VTE,	 including	 IDDVT,	 proximal	 DVT,	 PE	 or	 deep	 venous	thrombosis	 in	 other	 	 sites	 .	 All	 events	 were	 locally	 adjudicated	 after	 the	evaluation	of	specific	clinical	documentation.	Proximal	DVT	was	adjudicated	if	documented	by	a	compression	or	duplex	ultrasound.	Recurrent	IDDVT	was	adjudicated	in	the	presence	of	thrombosis	of	a	previously	normal	vessel	or	in	a	 previously	 completely	 recanalized	 distal	 venous	 segment.	 PE	 was	adjudicated	 when	 documented	 by	 a	 positive	 computed	 tomography	pulmonary	angiography	or	high	probability	perfusion	lung	scan.	Secondary	outcomes	were	major	bleeding	(according	to	the	definition	of	the	International	 Society	 on	 Thrombosis	 and	 Haemostasis	 [20])	 and	 overall	mortality.	
Statistical	Analysis.	Continuous	data	are	presented	with	mean	and	standard	deviations	 (SD)	 or	median	 and	 interquartile	 range	 (IQR)	 according	 to	 their	distribution,	 after	 applying	 	 the	 Kolmogorov-Smirnov	 test.	 A	 multivariate	Cox-regression	 analysis	 was	 performed	 to	 calculate	 the	 hazard	 ratio	 (HR)	and	 95%	 confidence	 interval	 (CI)	 associated	 with	 potential	 predictors	 of	recurrent	 VTE,	 after	 maintaining	 variables	 resulted	 at	 least	 marginally	significant	 	 (p<.10)	 at	 the	univariate	 analysis.	 IBM	SPSS	 Statistics	 software,	version	19	(SPSS,	Inc.,	IBM	corporation,	U.S.,	Armonk,	NY,	USA)	was	used	for	all	the	analyses.	
Trombosi	venose	profonde	distali		
	
	 27	
	
Results		A	 total	 of	 321	 patients	 with	 IDDVT	 were	 included	 in	 the	 study.	 Baseline	characteristics	are	presented	 in	Table	1.	Median	age	was	64	years	(IQR	46-76),	 55.1%	 were	 female.	 	 According	 to	 underlying	 VTE	 risk	 factors,	 165	IDDVTs	 (51.4%)	 were	 classified	 as	 provoked	 by	 transient	 risk	 factors	(trauma	22.1%,	surgery	9.3%,	bed	rest	>3	days	8.1%,	and	oral	contraceptives	8.4%	were	the	most	common),	55	(17.1%)	were	associated	with	cancer,	and	96	 (29.9%)	 were	 unprovoked;	 72	 patients	 (22.4%)	 had	 a	 previous	 VTE.	Anticoagulant	 treatment	was	administered	for	4	to	6	weeks	 in	288	patients	(89.7%)	 (284	with	 LMWH	alone	 and	4	with	 LMWH	 for	 at	 least	 5	 days	 and	warfarin);	 13	 patients	 (4.2%)	 received	 LWMH	 for	 at	 least	 5	 days	 and	warfarin	 for	 3	 to	 6	 months	 or	 indefinitely	 because	 of	 previous	 VTE;	 20	patients	 (6.2%)	 received	 a	 shorter	 course	 of	 LMWH	 due	 to	 pre-existing	anemia	and/or	thrombocytopenia	(7	patients)	or	because	of	pre-existing	(3	patients)	 or	 subsequent	 (6	 patients)	 bleeding	 complications,	 or	 upon	decision	 of	 the	 family	 doctor	 (4	 patients).	 Among	 the	 288	 patients	 who	initially	 received	 therapy	 for	 4	 to	 6	 weeks,	 42	 (14.6%)	 continued	 on	prophylactic	or	 intermediate	dose	LMWH	for	some	additional	weeks	(range	1-104)	 because	 of	 the	 persistence	 of	 risk	 factors	 (e.g.	 immobilization,	pregnancy	and/or	puerperium,	cancer).	Follow-up	was	complete	 for	97.5%	patients	(8	patients	were	 lost	 to	 follow-up),	and	data	on	mortality	were	retrieved	for	99.1%	of	patients	(3	were	lost	to	follow-up).	During	 a	 mean	 follow-up	 of	 41.5	 months	 (SD	 27.9),	 48	 patients	 (15%)	experienced	 a	 recurrent	 VTE,	 for	 an	 annualized	 recurrence	 rate	 of	 4.1	 per	100	 person-years.	 Recurrent	 VTE	 events	 were	 recurrent	 IDDVT	 in	 21	patients	 (43.8%),	 proximal	 DVT	 in	 10	 patients	 (20.8%),	 PE	 in	 15	 patients	(31.3%),	 and	 deep	 venous	 thrombosis	 in	 other	 sites	 in	 2	 patients	 	 (4.2%)	(Table	2).	
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Table	 3	 shows	 the	 results	 of	 univariate	 and	 multivariate	 analysis.	 Among	potential	predictors	of	recurrence,	only	unprovoked	IDDVT	and	the	presence	of	 active	 cancer	 remained	 significantly	 associated	 with	 recurrent	 VTE	 at	multivariate	analysis	(HR	2.11,	95%	CI	1.09-4.11,	and	HR	2.68,	95%	CI	1.13-6.36,	 respectively).	 The	 annualized	 rate	 of	 recurrent	 VTE	was	 6.8	 per	 100	patient-years	 after	 unprovoked	 IDDVT	 and	 9.7	 per	 100	 patient-years	 after	IDDVT	associated	with	active	cancer	(as	compared	with	2.2	per	100	patient-years	after	provoked	IDDVT,	p	=.004,	log-rank	test)	During	 anticoagulant	 treatment,	 6	 patients	 (1.9%)	 experienced	 major	bleeding,	 none	 was	 fatal.	 	 During	 the	 entire	 follow-up	 period,	 62	 patients	(19.3%)	died.		
Discussion	In	this	large	retrospective	cohort	study	of	patients	with	symptomatic	IDDVT,	who	were	treated	with	a	short	course	of	anticoagulation	in	90%	of	cases	(4	to	6	weeks),	and	who	were	followed	for	3.5	years	on	average,	we	found	a	non-negligible	rate	of	recurrent	VTE	(15%	of	patients,	4.1	per	100	patient-years).	More	than	half	of	recurrent	events	occurred	in	the	proximal	veins	or	as	PE,	.	Recurrence	 rates	 were	 	 significantly	 higher	 in	 patients	 with	 an	 index	unprovoked	event	or	with	active	cancer	(6.8	and	9.7	per	100	patient-years,	respectively),	as	compared	to		patients	with	a	transient	provoking	factor	(2.2	per	100	patient-years).		Previous	studies	on	IDDVT	were	quite	heterogeneous	in	terms	of	number	of	patients	 enrolled,	 type	 and	 duration	 of	 treatment	 and	 follow-up.	 In	 two	randomized	 controlled	 trials,	 the	 recurrence	 rate	 of	 VTE	 after	 IDDVT	 was	found	to	be	4%	and	2.6%	after	12	and	15	months	of	follow-up,	respectively,	in	 patients	 who	 received	 anticoagulation	 for	 12	 weeks	 or	 6/12	 weeks,	respectively	[12,21].	Higher	cumulative	rates	of	recurrence	were	described	in	more	recent	observational	studies,	which	present,	however,	some	important	limitations.	 In	one	study,	a	VTE	recurrent	rate	of	18.8%	was	 found	after	27	months	 of	 follow-up,	 but	 the	 duration	 of	 treatment	was	 heterogenous	 and	
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27%	of	patients	were	lost	to	follow-up	[9];	another	study	found	a	20%	VTE	recurrence	after	67	months,	but	only	56	patients	were	enrolled	[22].	Finally,	data	on	a	 large	number	of	patients	with	 IDDVT	(almost	2000)	are	available	from	 the	 international	 RIETE	 registry,	 but	 the	 follow-up	 was	 of	 3	 months	only,	during	which	2%	of	patients	experience	recurrent	VTE	[23].	Therefore,	our	study	may	be	considered	innovative	and	shows	several	strenghts,	being	conducted	 on	 a	 large	number	 of	 patients,	who	were	 treated	homogenously	and	followed	for	more	than	3	years,	with	negligible	loss	to	follow-up	(<	3%).	More	 recently,	 the	 results	 of	 a	 multicenter	 prospective	 cohort	 study	(OPTIMEV	 study),	 enrolling	 490	 patients,	 were	 published	 [13].	 Differently	from	 our	 study,	 patients	 with	 cancer	 or	 a	 personal	 history	 of	 VTE	 were	excluded	and	the	median	duration	of	treatment	was	significantly	longer	than	in	 our	 study	 (92	 days,	 IQR	 61-123	 and	 42	 days,	 IQR	 35-42,	 respectively).	These	 differences	 may	 explain	 the	 lower	 rate	 of	 recurrent	 VTE	 in	 the	OPTIMEV	study	as	compared	to	our	study,	both	in	the	overall	population	(2.7	and	4.1	 per	 100	patient-years,	 respectively)	 and	 in	 patients	with	 provoked	IDDVT	 (1.4	 and	 2.2	 per	 100	 patient-years,	 respectively)	 or	 unprovoked	IDDVT	 (3.8	 and	 6.8	 per	 100	 patient-years,	 respectively).	 One	 similarity	between	 the	 OPTIMEV	 study	 and	 our	 study	 was	 in	 the	 failure	 to	 find	 any	significant	 difference	 in	 the	 risk	 of	 recurrent	 VTE	 between	 patients	presenting	 with	 axial	 vein	 involvement	 and	 patients	 with	 muscular	 vein	involvement.	Differently	from	the	OPTIMEV	study,	we	did	not	find	older	age	and	increasing	number	of	involved	veins		to	be	predictive	of	recurrent	VTE	at	multivariate	analysis.		In	addition,	our	results	are	similar	to	those	of	a	recent	prospective	 study	 enrolling	 90	 patients,	 that	 found	 a	 19%	 rate	 of	 VTE	recurrence	after	 two	years	 from	 IDDVT	 treated	with	LMWH	 for	30	days	or	with	VKAs	 for	3	months	 (according	 to	 the	presence	or	absence	of	 transient	risk	factors,	respectively)	[18].		The	results	of	our	study	confirm	that	the	risk	of	recurrent	VTE	after	treated	IDDVT	 is	 relevant	 in	 patients	 with	 an	 unprovoked	 event	 or	 with	 active	cancer.	 	 In	 patients	 with	 unprovoked	 event,	 we	 found	 a	 24%	 cumulative	
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incidence	 of	 recurrent	 VTE	 after	 3.5	 years.	 Interestingly,	 half	 of	 the	 events	occurred	during	the	first	year,	for	a	cumulative	incidence	of	12.5%	at	1	year,	an	 incidence	 that	 is	 quite	 similar	 to	 that	 of	 proximal	 DVT	 or	 PE	 [24].	However,	our	study	failed	to	identify	a	subgroup	of	patients	with	unprovoked	IDDVT	with	a	higher	risk	of	recurrent	VTE,	which	may	require	an	extended	or	indefinite	treatment	duration.		In	patients	with	IDDVT	and	cancer	we	found	a	12.7%	cumulative	incidence	of	recurrence	 at	 1	 year.	 	 Of	 particular	 note,	 recurrent	 events	 were	 either	proximal	DVT	and/or	PE	in	7	out	of	 	8	patient.	Recent	consensus	guidelines	on	 the	 treatment	 of	 VTE	 in	 cancer	 patients	 and	 clinical	 practice	 data	 from	international	 surveys	 do	 not	 specifically	 consider	 the	 issue	 of	 IDDVT	 [25].	Given	the	observed	risk	of	recurrence,	further	evidence	is	urgently	needed.		Current	 guidelines	 suggest	 that	 anticoagulation	 for	 IDDVT	 should	 be	 given	for	a	minimum	of	3	months,	as	for	patients	with	proximal	DVT	[15].	However,	this	 recommendation	 is	 based	 on	 low	 level	 of	 evidence.	 The	 results	 of	 our	study	 show	 that	 a	 short	 course	 of	 anticoagulation	 (4	 to	 6	 weeks)	 can	 be	adequate	 for	 a	 large	 proportion	 of	 patients,	 especially	 when	 IDDVT	 is	associated	 with	 a	 transient	 risk	 factors.	 This	 approach	 seems	 to	 be	reasonable,	 as	 confirmed	 by	 the	 results	 of	 other	 studies	 [18],	 and	 it	 also	supported	by	some	experts	[14].	Moreover,	several	additional	studies	used	a	similar	 short-term	 treatment	 [6,8,12,16,17],	 with	 similar	 results	 when	compared	 to	 longer	 durations	 [12].	 On	 the	 other	 hand,	 an	 extended	treatment	is	probably	necessary	for	a	non	negligible	proportion	of	patients	at	higher	 risk	 of	 recurrence	 (i.e.	 in	 presence	 of	 cancer	 or	 of	 an	 	 unprovoked	event	with	additional	risk	factors).	Our	 study	 has	 limitations.	 First,	 the	 retrospective	 design	 can	 be	 associated	with	 incomplete	 and/or	 inaccurate	 data.	 However,	 initial	 and	 follow-up	information	up	 to	6	months	were	prospectively	collected	and	electronically	recorded,	according	to	a	pre-existing	internal	protocol,	so	minimizing	the	risk	of	incompleteness.	Moreover,	all	patients	were	called	to	complete	at	least	a	2-
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year	follow-up	and	only	8	patients	(2.5%)	and	3	patients	(0.9%)	were	lost	to	follow-up	for	the	primary	outcome	and	mortality,	respectively.	Second,	there	may	have	been	recall	bias	if	patients	reported	as	recurrent	VTE	events	some	episodes	that	were	only	suspected.	Therefore,	we	asked	patients	to	 bring	 the	 clinical	 documentation	 to	 our	 center,	 in	 order	 to	 confirm	 only	objectively	diagnosed	events,	thus	minimizing	the	risk	of	overestimating	the	recurrence	rate.	On	the	other	hand,	patients	may	have	missed	to	report	some	recurrent	 VTE	 events:	 we	 tried	 minimize	 this	 risk	 by	 searching	 the	 entire	databases	of	our	center	(which	serves	as	referral	center	for	the	diagnosis	of	DVT	and	collects	all	ultrasound	reports	and	clinical	visits)	as	well	as	those	of	the	 radiology	 and	 emergency	 department	 units	 of	 our	 hospital,	 to	 look	 for	potential	records	of	recurrent	events.		Third,	 treatment	 was	 not	 identical	 for	 all	 patients.	 Although	 the	 internal	protocol	indicated	a	course	of	LMWH	for	4	to	6	weeks,	the	final	decision	was	still	left	to	the	attending	physician.	However,	about	90%	of	patients	received	LMWH	according	to	the	protocol.	Moreover,	the	scheduled	visit	at	the	end	of	treatment	made	 it	 possibile	 to	 verify,	 at	 least	 retrospectively,	 the	 type	 and	reasons	 of	 treatment	 modifications	 (eg	 low	 platelet	 count,	 bleeding,	 skin	reactions)	Finally,	 this	 is	a	single	center	study,	 thus	 limiting	 the	generalizability	of	 the	results.	 However,	 due	 to	 the	 retrospective	 nature	 of	 the	 study	 and	 to	 the	presence	of	pre-exisiting	treatment	and	follow-up	protocol	at	our	center,	we	had	 the	 possibility	 to	 minimize	 the	 risk	 of	 incomplete	 data	 and	heterogeneous	results.	In	 conclusion,	 the	 results	 of	 our	 study	 show	 that	 the	 long-term	 risk	 of	recurrence	after	treated	IDDVT	is	not	negligible	and	is	represented	by	major	VTE	 events	 in	more	 than	50%	of	 cases.	 Therefore,	 if	 some	 IDDVTs	may	 be	regarded	 as	 transient/benign	 conditions,	 many	 other	 cases	 should	 be	considered	 in	 the	 more	 complex	 context	 of	 major	 venous	thromboembombolic	 events.	 Indeed,	 patients	 with	 unprovoked	 IDDVT,	 as	well	as	other	patients	at	higher	risk	of	recurrence	(active	cancer,	history	of	
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VTE),	may	 benefit	 from	 an	 extended	 treatment	 period.	 Further	 studies	 are	needed	 to	 better	 identify	 IDDVT	 patients	 who	 may	 deserve	 prolonged	anticoagulation	 and	 to	 balance	 the	 risk	 of	 recurrence	 with	 the	 risk	 of	bleeding.	
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Tables	Table	1.	Baseline	characteristics		and	treatment	N.	of	patients	Median	age	(years)	Female/Male	 321	64	(IQR	46-76;	range	20	–92)	177/144	(55.1	/	44.9%)	Clinical	presentation				Pain				Edema				Redness	
	266	(82.9%)	198	(61.7%)	71	(22.1%)	Extension				Monolateral				Bilateral				Single	vein				Muscular				Axial				Both				Concomitant	SVT	
	312	(97.2%)	9	(2.8%)	262	(81.6%)	177	(55.1%)	108	(33.6%)	36	(11.2%)	53	(16.5%)	Risk	factors				Transient	risk	factor				Cancer/MPN				Unprovoked				Personal	history	of	VTE	
	165	(51.4%)	56	(17.4%)	96	(30.0%)	72	(22.4%)	Treatment				LMWH	for	4	to	6	weeks				Vitamin	K	antagonists				Other	treatment	
	288	(89.7%)	13	(4.0%)	20	(6.2%)	Legend:	 SVT	 Superficial	 vein	 thrombosis;	 MPN	 myeloproliferative	 neoplasm;	 VTE	 venous	thromboembolism;	LMWH	low	molecular	weight	heparin		Table	2.	Results	Primary	outcome				Mean	follow-up				Lost	to	follow-up				Patients	diagnosed	with	recurrent	VTE							PE	(+/-	associated	DVT)							Proximal	DVT							Isolated	distal	DVT							Unusual	site	thrombosis	
	41.5	months	(SD	27.9)	8	(2.5%)	48	(15%)	15	(31.3%)	10	(20.8%)	21	(43.8%)	2	(4.2%)	Secondary	outcomes				Major	bleeding				Minor	bleeding				Cutaneous	reactions	to	LMWH	
	6	(1.9%)	8	(2.5%)	4	(1.2%)	Legend:	 VTE	 venous	 thromboembolism,	 PE	 pulmonary	 embolism,	 DVT	 deep	 vein	thrombosis,	LMWH	low	molecular	weight	heparin	
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Table	3.	Cox-regression	analysis	Predictive	factors	 Univariate	analysis	HR,	95%	CI	 p	value	 Multivariate	analysis	HR	95%	CI	 p	value	Age	≥65	ys	 1.64	(0.92	-	2.9)	 0.09	 1.3	(0.72	-	2.36)	 0.38	Male	gender	 1.01	(0.57	-	1.79)	 0.97	 -	 	VTE	risk	factors	-	transient	-	cancer	-	unprovoked	
	1	3.02	(1.29	-	7.05)	2.5	(0.33	-	4.68)	
		0.01	0.00	
	1	2.68	(1.13	-	6.36)	2.11	(1.09	-	4.11)	
		0.03	0.03	IDDVT	location	-	muscular	veins	-	axial	veins	-	both	
	1	1.11	(0.62	-	2.02)	0.52	(0.12	-	2.19)	
		0.72	0.37	 -	 	IDDVT	extension	-	1	vein	-	≥	2	veins	 	1	0.53	(0.19	-	1.46)	 		0.21	 -	 	Unilateral	IDDVT	Bilateral	IDDVT	 1	0.05	(0	-	4476.7)	 	0.44	 -	 	Previous	VTE	 1.88	(1.03	-	3.42)	 0.04	 1.49	(0.8	-	2.77)	 0.22	Anticogulant	for		>	6	weeks	 0.53	(0.19	-	1.49)	 0.23	 -	 	Legend:	 VTE	 venous	 thromboembolism,	 IDDVT	 isolated	 distal	 deep	 vein	 thrombosis,	 HR	hazard	ratio				
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Figures	Figure	 1.	 Kaplan-Meier	 curve	 for	 recurrence	 free	 survival	 after	 provoked,	unprovoked	or	cancer-associated	IDDVT.	
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Gestione	delle	emorragie	in	pazienti	anticoagulati	
I	farmaci	anticoagulanti	“tradizionali”	(eparina	non	frazionata,	eparine	a	baso	 peso	 molecolare,	 fondaparinux,	 dicumarolici)	 e	 quelli	 di	 nuova	generazione	 o	 “diretti”	 (apixaban,	 edoxaban,	 rivaroxaban,	 dabigatran)	 sono	associati	ad	un	rischio	non	trascurabile	di	emorragia	maggiore,	intorno	al	1-4%	all’anno29,30,31.	In	aggiunta,	le	emorragie	maggiori	in	corso	di	trattamento	anticoagulante	 sono	 caratterizzate	 da	 un	 significativo	 case-fatality	 rate,	 in	particolare	 se	 avvengono	 in	 sede	 intracranica	 e/o	 nei	 primi	 mesi	 di	trattamento32.		Le	 misure	 generali	 di	 supporto	 sono	 fondamentali	 in	 caso	 di	sanguinamenti	 pericolosi	 per	 la	 sopravvivenza	 (reintegrazione	 dei	 fluidi,	trasfusione	 di	 globuli	 rossi,	 identificazione	 e	 trattamento	 della	 fonte	 di	sanguinamento),	 unitamente	 a	misure	 specifiche	per	 antagonizzare	 l’effetto	dell’anticoagulante	 coinvolto.	 Tuttavia,	 al	 momento,	 sono	 disponibili	 degli	antidoti	 solo	 per	 l’eparina	 non	 frazionata	 (solfato	 di	 protamina)	 e	 per	 i	farmaci	 dicumarolici	 (vitamina	 K).	 Inoltre,	 anche	 in	 caso	 di	 trattamento	dicumarolico,	 la	 somministrazione	dell’antidoto	 spesso	non	 è	 sufficiente	 ad	interrompere	 un	 sanguinamento	 maggiore,	 per	 cui	 è	 necessario	 infondere																																																									
29	Palareti	G,	Leali	N,	Coccheri	S,	et	al.	Bleeding	complication	of	anticoagulant	treatment:	an	inception-cohort,	prospective	collaborative	study	(ISCOAT).	Lancet	1996;	348:	423-8	30	Schulman	S,	Beyth	RJ,	Kearon	C,	et	al.	Hemorrhagic	complications	of	anticoagulant	and	thrombolytic	treatment:	American	College	of	Chest	Physicians	evidence-based	clinical	practice	guidelines	(8th	edition).	Chest	2008;	133	(6	Suppl.):	257S-98S	31	Dentali	F,	Riva	N,	Crowther	M,	et	al.	Efficacy	and	safety	of	the	novel	oral	anticoagulants	in	atrial	fibrillation:	a	systematic	review	and	meta-analysis	of	the	literature.	Circulation	2012;126:2381-91	32	Carrier	M,	Le	Gal	G,	Wells	PS,	et	al.	Systematic	review:	case-fatality	rates	of	recurrent	venous	thromboembolism	and	major	bleeding	events	among	patients	treated	for	venous	thromboembolism.	Ann	Intern	Med	2010;152:578-589	
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fattori	 della	 coagulazione	 attraverso	 concentrati	 protrombinici	 o	 plasma	fresco	 congelato.	 Per	 quanto	 riguarda	 gli	 antidoti	 specifici	 per	 i	 DOACs	(andexanet,	 idarucizumab,	 PER977),	 questi	 sono	 attualmente	 in	 fase	 di	sperimentazione,	 con	 idarucizumab	 che	 ha	 recentemente	 ottenuto	 una	approvazione	 accelerata	 da	 parte	 della	 Food	 and	 Drug	 Administration	(Ottobre	2015).	E’	 stata	 condotta	 una	 revisione	 della	 letturatura	 per	 raccogliere	 e	presentare,	con	approccio	clinico	basato	su	casi	clinici,	le	evidenze	disponibili	sulla	gestione	e	 trattamento	delle	emorragie	durante	terapia	anticoagulante	tradizionale	e	con	DOACs.		Viene	presentato	di	 seguito	 il	 testo	dell’articolo	 relativo	 revisione	della	letteratura	 sopracitato,	 che	 è	 stato	 pubblicato	 sulla	 rivista	Drugs	 (Donadini	MP,	 Ageno	 W,	 Douketis	 J.	 Management	 of	 patients	 who	 are	 bleeding	 on	conventional	 or	 new	 anticoagulants:	 a	 practical	 and	 case-based	 approach.	Drugs	2012;72(15):1965-75).		 			
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MANAGEMENT	OF	PATIENTS	WHO	ARE	BLEEDING	ON	CONVENTIONAL	
OR	NEW	ANTICOAGULANTS:	A	PRACTICAL	AND	CASE-BASED	APPROACH		Marco	P.	Donadini,	Walter	Ageno,	James	D.	Douketis		
Introduction	Anticoagulant	drugs	are	highly	effective	for	the	prevention	and	treatment	of	venous	 thromboembolism	(VTE)	and	the	prevention	of	stroke	and	systemic	embolism	in	patients	with	chronic	atrial	fibrillation	(AF)	or	prosthetic	heart	valves.	 The	 need	 for	 and	 duration	 of	 anticoagulant	 therapy	 is	 driven	primarily	by	the	indication	for	anticoagulation	but	is	coupled	with	individual	patient	characteristics	that	weigh	thrombotic	risks	against	bleeding	risks.	Anticoagulant-related	 bleeding	 is	 characterized	 according	 to	 its	 severity	 as	either	 major,	 clinically	 relevant	 non-major,	 or	 minor.	 Until	 recently,	 there	was	no	standardized	definition	of	bleeding,	resulting	in	heterogeneity	in	the	reported	 incidence	 of	 bleeding	 across	 studies	 assessing	 anticoagulant	therapy.[1]	The	International	Society	on	Thrombosis	and	Haemostasis	(ISTH)	proposed	 in	 2005	 a	 definition	 of	 major	 bleeding	 in	 non-surgical	 patients	which	comprised	fatal	bleeding	and/or	bleeding	in	a	critical	site	(intracranial,	intraspinal,	 intraocular,	 retroperitoneal,	 intra-articular,	 pericardial	 or	intramuscular	with	 compartment	 syndrome)	 or	 bleeding	 associated	with	 a	decrease	 in	hemoglobin	≥2	g/dL	or	 transfusion	of	≥2	units	of	 red	cells.[2]	A	similar	 definition	 is	 proposed	 by	 the	 ISTH	 for	 surgical	 patients,	 with	additional	parameters	that	account	for	surgical	site	bleeding.[3]	The	 management	 of	 anticoagulant-associated	 bleeding	 depends	 on	 the	severity	of	bleeding	and	is	anchored	on	general	measures,	which	include	fluid	resuscitation,	 red	blood	cell	 transfusion	and,	perhaps	most	 importantly,	 the	diagnosis	and	treatment	of	the	bleeding	site.	Additional	specific	interventions	are	 based	 on	 the	 potential	 reversibility	 of	 an	 anticoagulant	 with	 blood	products	and	the	existence	of	drug-specific	antidotes.	
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The	 objective	 of	 this	 review	 is	 to	 provide	 an	 evidence-based	 but	 practical	approach	 to	 anticoagulant-associated	 bleeding.	 Specifically,	 we	 aim	 to	juxtapose	 the	 management	 of	 patients	 who	 are	 receiving	 an	 ‘old	anticoagulant’	 and	bleed	with	 patients	who	develop	bleeding	while	 using	 a	‘new	anticoagulant’.	The	format	of	this	review	consists	of	illustrative	cases	of	anticoagulant-related	bleeding	 followed	by	an	evidence-based	discussion	of	our	suggested	management	approach.	
	
Management	of	anticoagulant	associated	bleeding	
Case	Scenario	1	-	Vitamin	K	Antagonists	A	 73-year	 old	 man	 who	 was	 recently	 hospitalized	 for	 decompensated	congestive	 heart	 failure	 is	 diagnosed	 with	 proximal	 deep	 vein	 thrombosis	(DVT)	and	commences	conventional	anticoagulant	therapy,	consisting	of	low-molecular-weight	heparin	(LMWH)	and	warfarin.	After	2	weeks	of	treatment,	the	 patient	 presents	 with	 headache	 and	 vomiting	 followed	 by	 a	 decreased	level	of	consciousness	and	is	transported	to	hospital.	Computed	tomography	(CT)	scan	of	 the	brain	shows	a	 large	 intra-parenchymal	bleed	 involving	 the	temporoparietal	and	occipital	regions.	The	INR	at	presentation	is	5.2.	Incidence,	Risk	Factors,	and	Case-fatality	of	VKA-associated	Bleeding	In	patients	who	are	receiving	vitamin	K	antagonists	(VKAs)	such	as	warfarin	the	risk	for	major	bleeding	is	1-2%	per	year,	based	on	findings	from	cohort	studies	 and	 randomized	 trials.[4,5]	 The	 risk	 for	 bleeding	 is	 likely	 higher	 in	unselected	 community-based	 patients,	 as	 is	 evidence	 in	 a	 Danish	 registry	study	where	the	annual	risk	for	bleeding	was	4.3%.[6]	Several	risk	factors	for	VKA-associated	bleeding	have	been	 identified,	 including	advanced	age	 (>65	years),	 previous	 bleeding,	 cancer,	 renal	 or	 hepatic	 impairment,	 anemia,	thrombocytopenia,	 concomitant	 use	 of	 antiplatelet	 drugs,	 previous	 stroke,	hypertension,	poor	anticoagulant	control,	recent	surgery,	alcohol	abuse,	and	frequent	 falls.[7,8]	 The	 importance	 of	 prompt	 and	 effective	 management	 of	such	 bleeding	 is	 illustrated	 by	 the	 case-fatality	 rate	 of	 VKA-associated	bleeding,	 which	 is	 11%	 (upper	 bound	 95%	 confidence	 interval	 [CI]:	 16%)	
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during	the	first	3	months	of	VKA	treatment	for	VTE	[9]	and	9%	(upper	bound	95%	CI:	22%)	thereafter	 [10].	 In	patients	with	VKA-associated	 intra-cerebral	bleeding,	 as	 described	 in	 the	 case	herein,	 the	 case-fatality	 is	 approximately	50%	 and	 survivors	 often	 have	 major	 irreversible	 neurological	 deficits,	thereby	highlighting	the	importance	for	the	prevention	and	prompt	reversal	of	such	bleeds.	[11]	Pharmacologic	Properties	of	VKAs	and	Reversal	Strategies	(Table	1)	Warfarin	 is	 probably	 the	 most	 commonly	 used	 VKA	 worldwide	 but	acenocoumarol	 and	 phenprocoumon	 also	 are	 used	 widely,	 especially	 in	Europe.	Warfarin	has	an	elimination	half-life	of	approximately	36-48	hours,	longer	 than	 acenocoumarol	 (6-8	 hours)	 but	 shorter	 than	 phenprocoumon	(96-140	 hours).[12]	 Several	 measures	 should	 be	 considered	 for	 the	management	 of	 VKA-associated	 bleeding,	 which	 depend	 on	 the	 severity	 of	bleeding	and,	in	turn,	the	need	for	urgent	reversal.	These	measures	include:	i)	 interruption	 of	 VKA	 alone	 without	 additional	 interventions,	 typically	 for	minor	and/or	self-limiting	bleeds;	ii)	 administration	of	 intravenous	vitamin	K,	 5.0-10	mg,	by	 slow	 infusion,	 in	cases	of	severe	bleeding	(e.g.,	gastrointestinal),	or	oral	vitamin	K,	1.0-2.5,	mg	for	less	severe	,	self-limiting	bleeding	(e.g.,	hemorrhoids,	epistaxis);	iii)	 infusion	 of	 fresh	 frozen	 plasma	 (FFP)	 or	 prothrombin	 complex	concentrates	(PCC);	and	iv)	infusion	of	recombinant	activated	factor	VII	(rFVIIa).			 In	 patients	 with	 VKA-associated	 major	 bleeding,	 vitamin	 K1	(phytonadione)	 is	 the	 antidote	 for	 VKAs	 and	 should	 be	 routinely	administered	(the	need	to	administer	vitamin	K	also	to	patients	treated	with	the	 short-acting	 acenocoumarol	 has	 been	 less	 investigated)	 to	 ensure	neutralization	 of	 the	 anticoagulant	 effect,	 especially	 if	 the	 clinical	 course	 of	the	bled	 is	uncertain.	Vitamin	K	 can	be	given	 intravenously	 (1.0-2.5	mg)	 to	obtain	a	more	rapid	reduction	of	the	INR	that	begins	within	2	hours	and	may	be	 complete	within	 24	 hours,	 depending	 on	 the	 baseline	 INR.	 To	minimize	the	 risk	 of	 anaphylactoid	 reactions	 caused	 by	 intravenous	 vitamin	 K	
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administration	(approximately	3	per	10,000),	vitamin	K	should	be	mixed	 in	50	mL	of	fluid	and	infused	slowly	over	20-30	minutes.[12-15]	It	 is	 noteworthy	 that	 in	 patients	 with	 VKA-associated	 bleeding	 a	coagulopathy	exists	for	a	considerable	time	after	the	last	dose	of	the	VKA	as	it	takes	the	liver	between	12	and	100	hours	to	restore	(to	at	least	50%	levels)	the	 vitamin	 K-dependent	 factors	 II,	 VII,	 IX,	 and	 X	 (based	 on	 a	 half-life	 of	 6	hours	for	factor	VII	and	50	hours	for	factor	II).[16]	Consequently,	in	the	setting	of	a	 life-threatening	bleed,	coagulation	factor	replacement	is	advised.	FFP	is	one	 option	 for	 VKA-associated	 bleeding,	 administered	 at	 a	 dose	 of	 15	mL/kg.[17]	However,	the	use	of	FFP	for	patients	with	VKA-associated	bleeding	has	drawbacks,	which	include:		i) variable	 quantities	 of	 vitamin	 K-dependent	 coagulation	 factors	 per	unit	of	FFP;		ii) need	for	AB0	blood	group	cross-matching	(if	not	already	available);		iii) time	 required	 to	 thaw	 (stored	 at	 40C)	 and	 infuse	 FFP	 (time	 from	request	of	FPP	to	completion	of	transfusion	can	take	several	hours);[18]	iv) risk	for	volume	overload	with	4-8	units	of	FFP	transfusion	(1	unit	FFP	contains	180-300	mL	fluid);	and		v) risk	 for	 transfusion	 associated	 lung	 injury	 (TRALI)	 -	 a	 rare	 form	 of	non-cardiogenic	pulmonary	edema	occurring	with	rapid	FFP	infusion	[19].		In	recent	years,	PCCs	have	become	available	for	VKA-associated	bleeding	and	have	advantages	over	FFP,	which	include:		i) providing	 consistent	 quantities	 of	 vitamin	 K-dependent	 coagulation	factors;		ii) no	 need	 for	 AB0	 blood	 group	 cross-matching	 (due	 to	 purification	process,	 that	 also	 makes	 PCC	 safer	 in	 terms	 of	 the	 transmission	 of	pathogens);[20]		iii) less	 time	 for	 its	 preparation	 (stored	 at	 room	 temperature	 as	 a	lyophilized	powder	and	reconstituted	with	sterile	water);	and	iv) no	risk	for	volume	overload	(total	volume	<50	mL).		
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PCCs	are	available	as	3-factor	(II,	IX,	and	X)	PCCs,	4-factor	(II,	VII,	IX,	and	X)	PCCs	 (e.g.,	 Octaplex®,	 Beriplex®),	 or	 activated	 4-factor	 PCCs	 (e.g.,	 FEIBA®	 -	factor	 eight	 inhibitor	 bypass	 activity).	 PCCs	 are	 infused	 at	 a	 rate	 of	 20-50	IU/kg	over	15-30	minutes.	 INR	correction	 is	more	rapid	with	PCC	than	FFP	and	can	be	achieved	in	about	3-5	hours.[13,21]	Although	the	absence	of	clinical	outcome-driven	 trials	 comparing	 FFP	 and	 PCC	 for	 VKA-associated	 bleeding	precludes	definitive	 recommendations,	 these	 advantages	 of	 PCCs	 should	be	considered	when	managing	 patients	with	 VKA-associated	 bleeding.	 Indeed,	from	a	practical	perspective,	PCCs	may	be	considered	as	first-line	treatment	for	 patients	 with	 life-threatening	 or	 intracranial	 VKA-associated	 bleeding	where	rapidity	of	availability	and	targeted	clotting	factor	administration	may	be	 desirable.[22]	 .	 Moreover,	 it	 should	 be	 noted	 that	 PCCs	 are	 relatively	expensive,	 at	 approximately	 $2,000-$2,500	 per	 infusion	 (compared	 with	approximately	 $200-$300	 for	 4	 units	 FFP)	 but	 less	 so	 than	 recombinant	activated	 factor	 VII	 (rFVIIa),	 at	 approximately	 $5,000-$5,500	 per	 infusion.	From	 a	 practical	 perspective,	 it	 is	 reasonable	 to	 consider	 PPCs	 as	 first-line	treatment	 to	 correct	 the	 coagulopathy	 in	 patients	 with	 life-threatening	 or	intracranial	 VKA-associated	 bleeding	 and	 to	 consider	 FFP	 in	 less	 severe	bleeding,	especially	if	PCCs	are	not	readily	available.		Irrespective	 of	 whether	 FFP	 or	 PCC	 is	 administered	 for	 VKA-associated	bleeding,	the	long	half-life	of	VKAs	coupled	with	the	short	half-lives	of	infused	coagulation	 factors	 mandates	 the	 use	 of	 vitamin	 K	 in	 most	 VKA-treated	patients	 as	 an	 antidote	 to	 warfarin	 so	 as	 to	 restore	 the	 endogenous	production	of	vitamin	K-dependent	coagulation	factors.		Finally,	 in	 the	 setting	 of	 VKA-associated	 bleeding,	 evidence	 supporting	 the	use	of	rFVIIa	is	limited.	Its	use	may	be	suggested	in	cases	of	life-threatening	bleeding	 when	 coagulation	 factor	 replacement	 products	 do	 not	 have	 the	desired	 effect	 or	 in	 patients	 who	 will	 not	 accept	 any	 blood	 product	transfusions.[12]	
	
Case	Scenario	2	-	New	Oral	Anticoagulants		
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A	 76-year	 old	 woman	 with	 hypertensive	 cardiomyopathy	 and	 diabetes	 is	found	 to	 have	 AF	 on	 a	 routine	medical	 visit,	which	 is	 confirmed	 on	 repeat	testing.	Treatment	options	for	stroke	prevention	include	dabigatran,	150	mg	twice-daily,	or	warfarin,	administered	to	achieve	a	targeted	INR	of	2.5	(range:	2.0-3.0).	Dabigatran	was	chosen	because	of	its	ease	of	administration.	After	2	months	of	 treatment,	 the	patient	presents	with	two	episodes	of	melena	and	superimposed	 fatigue.	 On	 physical	 examination,	 there	 is	 palor,	 blood	pressure	 was	 85/50	 mmHg,	 and	 the	 heart	 rate	 was	 110	 beats/minute.	Hemoglobin	 was	 7.5	 g/dL.	 Esophagogastroduodenoscopy	 and	 colonoscopy	did	not	reveal	a	source	of	bleeding.		Incidence	 and	 Case-fatality	 of	 Bleeding	 Associated	 with	 New	 Oral	Anticoagulant	In	recent	years,	the	emergence	of	new	oral	anticoagulants	(NOACs)	provides	clinicians	with	alternatives	to	VKAs	for	patients	with	AF	or	VTE.	Among	the	NOACs,	 the	 oral	 factor	 II	 inhibitor	 dabigatran	 and	 oral	 factor	 Xa	 inhibitors	rivaroxaban	 and	 apixaban	 have	 completed	 phase	 III	 trials.	 Dabigatran	was	approved	by	the	Food	and	Drug	Administration	(FDA)	in	the	United	States	in	October	 2010	 for	 stroke	 prevention	 in	 AF,	 becoming	 the	 first	 new	 oral	anticoagulant	to	be	available	for	this	clinical	indication	in	more	than	50	years.	The	European	Medicines	Agency	(EMA)	also	approved	dabigatran	and,	more	recently,	 rivaroxaban	 for	 the	 same	 clinical	 indication.	 In	 addition,	 the	 EMA	approved	rivaroxaban	 for	 the	 treatment	of	acute	DVT	(both	dabigatran	and	rivaroxaban	were	already	approved	 in	US	and	Europe	 for	 the	prevention	of	VTE	after	orthopedic	surgery).		In	phase	III	trials	involving	patients	with	AF,	dabigatran	was	found	to	be	non-inferior	to	warfarin	for	preventing	stroke	and	systemic	embolism	at	a	dose	of	110	mg	bid	and	superior	to	warfarin	at	a	dose	of	150	mg	bid.[23]	Rivaroxaban	at	a	dose	20	mg	od	was	non-inferior	to	warfarin	for	the	same	outcome.[24]		In	terms	of	bleeding	events,	dabigatran	150	mg	bid	was	not	associated	with	an	 increased	 risk	 of	 major	 bleeding	 (3.11%/year	 vs.	 3.36%/year,	respectively,	 p=0.31)	 whereas	 dabigatran	 110	mg	 bid	 was	 associated	 with	
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less	 major	 bleeding	 than	 warfarin	 (2.71%/year,	 p=0.003).[23]	 Interestingly,	the	only	dose	of	dabigatran	approved	by	the	FDA	for	patients	without	renal	impairment	 (150	 mg	 bid)	 was	 associated	 with	 an	 increased	 risk	 of	gastrointestinal	bleeding	(RR	1.50,	95%	CI:	1.19-1.89)	and	a	reduced	risk	of	intracranial	 bleeding	 (RR	 0.40,	 95	 %	 CI:	 0.27-0.60)	 compared	 with	warfarin.[23]		The	risk	of	major	bleeding	for	rivaroxaban	and	warfarin	was	similar	(3.6	vs	3.4	per	100	patient-years,	respectively,	p=0.58);	rivaroxaban	was	associated	with	 less	 intracranial	 bleeding	 compared	 with	 warfarin	 (0.5	 vs.	 0.7/100	patient-years,	respectively,	p=0.02)	but	more	gastrointestinal	major	bleeding	(3.2%	vs.	2.2%).[24]	In	 phase	 III	 trials	 on	 VTE	 treatment,	 rivaroxaban	 was	 non-inferior	 to	warfarin	for	the	prevention	of	recurrent	VTE	[25,26],	and	the	number	of	major	bleeding	 events	 were	 similar	 among	 patients	 receiving	 rivaroxaban	 and	warfarin	treated	for	acute	DVT	(0.8%	vs	1.2%,	p=0.21),[25]	whereas	there	was	less	major	bleeding	associated	with	rivaroxaban	in	patients	treated	for	acute	pulmonary	embolism		(1.1%	vs.	2.2%,	p=	0.003)[26].		Data	on	the	case-fatality	of	NOAC-associated	are	not	yet	available.	However,	the	 case-fatality	 probably	 is	 similar	 (and	 possibly	 less,	 due	 to	 fewer	intracranial	 bleeds)	 to	 that	 of	 VKA-associated	 bleeding.	 In	 support	 of	 this	contention,	 an	 assessment	 of	 bleeding	 associated	 with	 ximelagatran,	 the	prototype	 oral	 direct	 thrombin	 inhibitor	 that	 was	 withdrawn	 from	 clinical	use	 because	 of	 hepatotoxicity,	 showed	 similar	 case-fatality	 rates	 compared	with	warfarin.[27]	Pharmacologic	 Properties	 of	 New	 Oral	 Anticoagulants	 and	 Implications	 for	Reversal	(Table	1)	Dabigatran	 is	 a	 selective	 and	 reversible	 oral	 direct	 thrombin	 inhibitor.	 It	 is	administered	as	a	prodrug	(dabigatran	etexilate)	that	is	rapidly	adsorbed	in	the	stomach	and	small	intestine	and	converted	to	its	active	form,	dabigatran,	by	 rapidly	 acting	 serine	 esterase-catalyzed	 hydrolysis.[28]	 The	 key	pharmacologic	properties	of	dabigatran	include	a	time	to	peak	action	of	1-3	
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hours,	 blood	protein	binding	of	 30-35%,	 and	 approximately	80%	clearance	by	the	kidney.	Rivaroxaban	is	a	selective	and	reversible	oral	direct	factor	Xa	inhibitor.	Its	key	pharmacologic	properties	include	a	time	to	peak	action	of	1-3	hours,	blood	protein	binding	of	92-95%,	and	33%	clearance	by	the	kidney	for	 the	 active	 form	 of	 the	 drug	 (30%	 renal	 clearance	 of	 inactive	 form).[29]	Apixaban	 is	 another	 selective	 and	 reversible	 oral	 direct	 factor	 Xa	 inhibitor	and,	 as	 with	 rivaroxaban	 and	 dabigatran,	 has	 a	 rapid	 peak	 action	 of	 1-3	hours.	Blood	protein	binding	is	approximately	80%	and	25-27%	of	the	drug	is	cleared	by	the	kidney.	One	of	 the	advantages	of	 the	NOACs	 is	 their	 shorter	half-lives	 compared	 to	warfarin:	12-17	hours	for	dabigatran;	7-11	hours	for	rivaroxaban;	and	8-10	hours	for	apixaban,	as	compared	with	36-48	hours	for	warfarin.[29]	However,	unlike	with	warfarin,	 the	 half-lives	 of	 NOACs	 can	 increase	 in	 patients	with	moderate-to-severe	renal	 impairment,	especially	for	dabigatran.[30,31]	One	of	the	disadvantages	of	the	NOACs	is	the	lack	of	drug-specific	antidotes	although	the	development	of	such	antidotes	are	in	progress.		A	suggested	management	approach	to	bleeding	in	patients	who	are	receiving	a	NOAC	is	provided	below.	However,	it	should	be	emphasized	that	given	the	relatively	 short	half-lives	of	NOACs,	 it	may	be	 sufficient	 to	 simply	withhold	further	 NOAC	 doses	 without	 the	 need	 for	 blood	 product	 administration,	especially	in	patients	with	non-life-threatening	bleeding	or	patients	in	whom	the	source	of	bleeding	has	been	identified	and	treated	(e.g.,	electrocautery	of	a	bleeding	peptic	ulcer).	In	addition	to	the	abovementioned	general	measures	(fluid	 resuscitation,	 red	 blood	 cell	 transfusion,	 diagnostic	 and	 therapeutic	procedures	on	the	source	of	bleeding),	other	interventions	may	include:	i)	interruption	of	the	drug;	ii)	FFP	or	PCC;	iii)	rVIIa;		iv)	 hemodialysis	 (dabigatran	 only	 as	 rivaroxaban	 and	 apixaban	 are	 highly	protein	bound	and	cannot	be	dialyzed);	and		
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v)	 activated	 charcoal	 and/or	 gastric	 lavage	 may	 be	 considered	 in	 selected	patients,	for	example	those	with	a	known	NOAC	overdose.		In	 the	 setting	 of	 major	 bleeding,	 the	 interruption	 of	 dabigatran	 and	rivaroxaban	alone	is	not	sufficient,	considering	their	half-life	and	the	ongoing	inhibition	 of	 factors	 II	 and	 X.	 Administration	 of	 activated	 charcoal	 may	prevent	further	drug	absorption	if	done	within	a	few	hours	of	drug	ingestion	although	 NOAC-specific	 clinical	 data	 to	 support	 such	 interventions	 are	lacking.	Oral	activated	charcoal	appears	effective	in	absorbing	dabigatran	in	an	 in	 vitro	 model	 [32],	 whereas	 no	 comparable	 data	 are	 available	 for	rivaroxaban.	 Overall,	 there	 are	 no	 clinical	 data	 to	 support	 the	 efficacy	 of	activated	 charcoal	 and/or	 gastric	 lavage	 in	 patients	 with	 NOAC-associated	bleeding.		In	 studies	 involving	 a	 murine	 model	 of	 intracranial	 hemorrhage,	 FFP	 was	tested	to	reduce	hematoma	expansion	provoked	by	dabigatran	but	there	was	no	 effect	 on	mortality.[33]	 It	 is	 unclear	whether	 these	 results	 correlate	with	FFP	use	in	humans.	No	clinical	data	are	available	on	the	use	of	FFP	in	patients	with	dabigatran-	or	rivaroxaban-associated	bleeding.		The	efficacy	of	4-factor	PCC	to	reverse	the	anticoagulant	effect	of	dabigatran	and	 rivaroxaban	was	 tested	 in	 a	 randomized,	 placebo-controlled,	 crossover	trial	 in	 healthy	 subjects.[34]	 The	 prolongation	 of	 aPTT,	 thrombin	 time	 and	ecarin	clotting	time	induced	by	dabigatran	was	not	reversed	by	the	4-factor	PCC.	 On	 the	 other	 hand,	 the	 prolongation	 of	 PT	 and	 endogenous	 thrombin	potential	(ETP)	induced	by	rivaroxaban	was	normalized	by	the	4-factor	PCC,	suggesting	 the	 possibility	 to	 reverse	 rivaroxaban	 action	 by	 the	 4-factor	PCC.[34]	 However,	 the	 ability	 to	 arrest	 bleeding	 in	 rivaroxaban-treated	patients	 needs	 further	 research.	 These	 findings	 on	 the	 ability	 of	 PCCs	 to	reverse	the	action	of	rivaroxaban	but	not	of	dabigatran	have	been	confirmed	in	 another	 study	 on	 healthy	 volunteers;	 on	 the	 other	 hand,	 this	 study	suggests	a	potential	role	of	FEIBA®	(4-factor	activated	PCC)	in	patients	with	dabigatran-associated	bleeding.[35]		
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With	regard	to	the	use	of	rVIIa,	it	significantly	reduced	the	bleeding	time	that	was	 increased	 by	 dabigatran	 in	 a	 rat	 model;	 however,	 among	 coagulation	tests,	 only	 the	 PT	 returned	 to	 normal	 after	 rVIIa	 administration,	 but	 not	aPTT,	thrombin	time	and	ecarin	clotting	time.[36]	In	a	mouse	model,	rVIIa	did	not	 prevent	 intracerebral	 hematoma	 expansion	 in	 mice	 receiving	dabigatran.[33]	With	regard	to	rivaroxaban,	rVIIa	reduced	bleeding	time	that	was	 increased	by	rivaroxaban	 in	a	rat	and	a	baboon	model.[37,38]	No	clinical	data	 are	 available	 currently	 on	 the	 use	 of	 rVIIa	 for	 bleeding	 reversal	 or	 its	effects	on	coagulation	parameters	in	patients	treated	with	either	dabigatran	or	rivaroxaban.	Finally,	 hemodialysis	 can	 be	 an	 option	 only	 for	 non-highly	 protein-bound	drugs,	 such	as	dabigatran	 (and	not	 rivaroxaban	or	 apixaban).	Hemodialysis	was	 able	 to	 remove	more	 than	60%	of	dabigatran	at	2	hours	 in	 volunteers	receiving	hemodialysis	for	end-stage	renal	disease.[39]	Hemoperfusion	proved	effective	to	eliminate	dabigatran	only	in	an	in	vitro	model.[32]		Considering	 the	 paucity	 of	 available	 evidence	 regarding	 the	 reversal	 of	NOAC-associated	 bleeding,	 pragmatic	 guidance	 was	 recently	 provided	 by	members	of	North	American	thrombosis	and	hemostasis	scientific	societies.	The	use	of	FFP	was	considered	not	likely	to	be	helpful	in	this	setting,	whereas	the	use	of	PCC	was	considered	to	be	a	reasonable	approach	in	the	opinion	of	several,	but	not	all,	authors	(due	to	absence	of	clinical	data).	The	usefulness	of	rVIIa	for	new	oral	anticoagulation	reversal	was	considered	unclear.[40]			
Case	 Scenario	 3	 -	 Parenteral	 Anticoagulants	 (unfractionated	 heparin	 [UFH],	
low-molecular-weight	heparin	[LMWH],	fondaparinux)	An	 83-year	 old	 woman	 is	 receiving	 LMWH	 for	 treatment	 of	 right	 leg	superficial	vein	thrombosis,	diagnosed	3	weeks	ago,	now	presents	with	pain	and	swelling	of	 the	 left	 lower	 limb,	which	began	3	days	before.	On	physical	examination	there	is	a	large	hematoma	on	the	posterior	side	of	the	left	thigh;	the	 hemoglobin	 level	 was	 8.2	 g/dL.	 A	 CT-angiography	 confirmed	 the	presence	 of	 a	 hematoma	 of	 the	 quadriceps,	 extending	 for	 about	 25	 cm	
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longitudinally;	there	was	no	arterial	bleeding	at	that	site,	whereas	it	was	not	sufficiently	clear	whether	some	small	venous	active	bleeding	was	present.	Bleeding	Risk	Associated	with	Parenteral	Anticoagulants	The	 incremental	 risk	 of	major	 bleeding	 associated	with	 treatment	 doses	 of	UFH	 or	 LMWH	 (i.e.,	 enoxaparin	 1	mg/kg	 bid)	 compared	 to	 placebo	 is	 less	than	2%.[8]	In	trials	comparing	LMWH	to	VKAs	for	the	long-term	treatment	of	VTE,	 the	risk	of	major	bleeding	associated	with	LMWH	was	not	statistically	different	 from	 that	 associated	 with	 warfarin	 (RR	 	 =	 0.81,	 95%	 CI:	 0.81-1.22).[7]	 The	 risk	 of	 major	 bleeding	 associated	 with	 treatment	 doses	 of	fondaparinux	(i.e.,	7.5	mg	daily)	in	patients	with	acute	VTE	does	not	appear	to	differ	to	that	of	LMWH	(RR	=	0.93,	95%	CI:	0.43-2.03	in	the	DVT	trial;	RR	=	0.85,	 95%	 CI:	 0.49-1.49	 in	 the	 PE	 trial).[41,42]	 In	 a	 placebo-controlled	 trial	assessing	a	45-day	course	of	a	lower	dose	of	fondaparinux	(i.e.,	2.5	mg	daily)	for	 the	 treatment	 of	 superficial	 vein	 thrombosis,	 the	 incidence	 of	 major	bleeding	was	low	(~1	in	1,500	patients	in	either	arm).[43]	Pharmacologic	 Properties	 of	 Parenteral	 Anticoagulants	 and	 Reversal	Strategies	(Table	1)	UFH	 can	 be	 administered	 by	 continuous	 intravenous	 infusion	 or	 by	subcutaneous	 injection,	 with	 the	 intravenous	 route	 allowing	 rapid	 action	within	 minutes.	 UFH	 is	 cleared	 by	 a	 rapid	 saturable	 (cellular)	 dose-dependent	mechanism	 and	 a	 slower	 non-saturable	 dose-independent	 renal	mechanism.	After	stopping	the	infusion,	the	time	to	normalize	hemostasis	is	3-6	hours	for	intravenous	UFH	and	8-12	after	subcutaneous	UFH.[44,45]	LWMHs	 are	 administered	 subcutaneously	 and	 have	 advantages	 over	 UFH	that	 include	having	higher	bioavailability	 and	providing	a	more	predictable	anticoagulant	response.	After	absorption,	the	peak	anti-Xa	activity	occurs	at	3-5	 hours.	 Differing	 from	 UFH,	 their	 elimination	 is	 predominantly	 by	 the	kidney	so	that	their	half-life	of	3-6	hours	may	be	prolonged	in	patients	with	moderate-to-severe	renal	dysfunction.[44]	
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Fondaparinux	is	administered	subcutaneously	and	is	rapidly	and	completely	absorbed.	It	is	excreted	unchanged	in	the	urine	and	it	has	a	half-life	of	15-17	hours.[46]	In	 case	 of	 major	 bleeding	 in	 UFH-treated	 patients,	 the	 infusion	 should	 be	interrupted	 immediately.	 Given	 the	 short	 half-life	 of	 intravenous	 UFH,	 this	first	 step	alone	 can	normalize	hemostasis	 in	3-4	hours.	However,	 if	 a	 rapid	reversal	 is	needed	 in	an	emergency	situation,	 this	can	be	achieved	by	using	intravenous	protamine	 sulfate,	 a	 specific	 antidote	 to	UFH.	The	aPTT	can	be	used	 to	 monitor	 the	 neutralization	 of	 the	 heparin	 effect.	 One	 milligram	 of	protamine	sulfate	can	reverse	approximately	100	units	of	UFH.	Importantly,	considering	 the	 short	 half-life	 of	 intravenous	 UFH	 of	 about	 60-90	minutes,	the	dosage	of	protamine	sulfate	needs	to	be	calculated	based	on	the	amount	of	 UFH	 infused	 in	 the	 last	 2-2.5	 hours.	 The	 reversal	 of	 subcutaneously	administered	UFH	may	require	a	prolonged	infusion	of	protamine	sulfate.[44]	It	 should	 be	 noted	 that	 protamine,	 which	 is	 derived	 from	 fish	 sperm,	 is	associated	 with	 allergic	 reactions,	 including	 cardiorespiratory	 collapse,	especially	in	patients	with	a	fish	allergy	or	men	who	have	had	a	vasectomy	in	whom	 the	 potential	 loss	 of	 the	 blood-testis	 barrier	 may	 lead	 to	 semen	antibody	development.[47,48]		In	LMWH-treated	patients	with	major	bleeding,	apart	 from	the	 interruption	of	 LMWH	 (that,	 alone,	 can	 restore	 hemostasis	 in	 about	 12-24	 hours	 only),	protamine	 sulfate	 is	 not	 as	 effective	 as	 for	 UFH.	 Indeed,	 protamine	 sulfate	neutralizes	 the	 anti-thrombin	 activity	 of	 LMWH	 but	 only	 part	 of	 its	predominant	anti-Xa	activity.	There	is	no	convincing	evidence	supporting	or	refuting	 a	 beneficial	 effect	 of	 protamine	 sulfate	 on	 LWMH-associated	bleeding.	 In	 recent	 clinical	 practice	 guidelines	 it	 is	 suggested	 that,	 in	 cases	where	 a	 LMWH	 effect	 needs	 to	 be	 neutralized,	 protamine	 sulfate	 can	 be	infused	at	a	dose	of	1	mg	per	100	anti-Xa	units,	if	LMWH	was	given	within	8	hours.[44]	 Evidence	on	 the	use	of	 rVIIa	 is	 limited	 to	 a	 single	 successful	 case	report.[49]		
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In	 fondaparinux-treated	 patients	 with	 bleeding,	 no	 approved	 antidotes	 are	available.	 Interruption	 of	 sc	 administration	 is	 needed	 as	 the	 first	 step.	 The	use	of	FFP	and/or	PCC	 is	not	 supported	by	adequate	evidence;[50]	 activated	PCC	(FEIBA®)	significantly	 reversed	 the	action	of	 fondaparinux	 in	vitro	 in	a	single	 study.[51]	 Two	 randomized	 placebo-controlled	 trials	 on	 healthy	subjects	evaluated	the	use	of	rVIIa,	showing	its	ability	to	normalize	the	aPTT,	PT	and	thrombin-generation	time	that	were	prolonged	by	fondaparinux.[52,53]	Recently,	 a	 specific	 antidote	 has	 been	 developed	 to	 neutralize	 the	 anti-Xa	activity	of	fondaparinux	in	vivo,[54]	that	need	to	be	tested	in	the	clinical	setting	of	fondaparinux-associated	bleeding.			The	use	of	PCC,	FPP	or	rFVIIa	has	not	been	assessed,	 to	our	knowledge,	 for	UFH-	 or	 LMWH-	 or	 fondaparinux-associated	 bleeding.	 Although	 a	 clinician	may	 not	 be	 faulted	 for	 administering	 one	 or	more	 of	 these	 agents	 for	 life-threatening	 or	 severe	 intracranial	 bleeding,	 emphasis	 should	 be	 placed	 on	antidote	administration	and	other	supportive	measures.			
New	Oral	Anticoagulants	and	Antidotes	Under	Investigation		Apixaban,	 as	 discussed	 earlier,	 has	 completed	 phase	 III	 trials	 for	 stroke	prevention	 in	 patients	 with	 AF	 and	 approval	 for	 this	 clinical	 indication	 is	likely	forthcoming	in	2012	[55,56];	phase	III	trials	for	the	treatment	of	VTE	are	ongoing.	As	of	mid-2012	apixaban	is	approved	for	clinical	use	(in	Canada	and	Europe)	only	as	DVT	prophylaxis	after	hip	or	knee	replacement	surgery.	No	clinical	 strategies	 for	 the	 reversal	 of	 its	 anticoagulation	 effect	 have	 been	tested	so	 far.	Two	other	oral	 factor	Xa	 inhibitors,	edoxaban	and	betrixaban,	are	also	in	earlier	stages	of	clinical	development.		A	 novel	 anticoagulant,	 idrabiotaparinux,	 has	 been	 developed	 by	 adding	 a	biotin	 moiety	 to	 idraparinux,	 a	 long-lasting	 inhibitor	 of	 factor	 Xa.	 This	modification	 does	 not	 change	 the	 efficacy	 and	 safety	 of	 idraparinux	 but	allows	rapid	reversal	of	its	anticoagulant	effect	through	the	infusion	of	avidin,	which	 tightly	 binds	 to	 biotin,	 if	 bleeding	 occurs.[57]	 If	 urgent	 reversal	 is	needed,	avidin	100	mg,	diluted	 in	100	mL	of	 isotonic	 saline,	 can	be	 infused	
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over	30	min.[58]	Idrabiotaparinux	is	non-inferior	to	warfarin	for	the	treatment	of	PE.[59]	Moreover,	new	antidotes	are	being	developed	in	recent	years.	Among	them,	a	recombinant	 antithrombin	 variant	 (AT-N135Q-Pro394)	 and	 a	 recombinant	factor-Xa	 variant	 (PRT064445)	 have	 shown	 to	 reverse	 the	 effect	 of	fondaparinux	 and	 LMWH	 in	 vitro	 and	 in	 animal	models.[60,61]	 Interestingly,	the	recombinant	 factor-Xa	variant	PRT064445	was	able	to	reverse	the	anti-Xa	 activity	 of	 rivaroxaban	 in	 experimental	 models,	 thus	 emerging	 as	 a	potential	antidote	to	new	oral	factor-Xa	inhibitors	for	the	clinical	setting.[60]	
	
Conclusions	Old	and	new	anticoagulants	are	associated	with	a	clinically	important,	1-4%	per	year,	risk	for	major	bleeding.	Rapid	reversal	of	their	anticoagulant	effect	is	desirable	when	major	bleeding	occurs	to	mitigate	the	associated	morbidity	and	mortality.	General	supportive	measures	are	 fundamental	 in	case	of	 life-threatening	 bleeding	 (fluid	 resuscitation;	 red	 blood	 cell	 transfusions;	diagnosis	 and	 treatment	 of	 bleeding	 site),	 along	 with	 specific	 measures	directed	to	reverse	the	effect	of	the	involved	anticoagulant.	Specific	antidotes	are	 currently	 available	 only	 for	 the	 oldest	 anticoagulants,	 UFH	 and	 VKAs.	However,	even	in	case	of	VKA-associated	bleeding,	the	administration	of	the	antidote	alone	is	not	sufficient	to	reverse	severe	bleeding,	thus	requiring	the	infusion	 of	 coagulation	 factors	 through	 PCC	 or	 FFP.	 The	 management	 of	bleeding	 during	 treatment	 with	 new	 oral	 anticoagulants	 requires	 further	clinical	 research,	 since	 available	 data	mainly	 come	 from	 in	 vitro	 or	 animal	models.	New	antidotes,	specifically	targeted	to	the	new	agents,	are	currently	under	 initial	 investigative	 steps	 and	may	 offer	 some	 important	 progress	 in	the	management	of	anticoagulated	patients,	if	their	efficacy	and	safety	will	be	confirmed	in	clinical	trials.				
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Conclusioni
I	 risultati	 del	progetto	di	 ricerca	hanno	portato	 ad	una	 conoscenza	più	approfondita	della	prognosi	di	due	manifestazioni	comuni	del	TEV,	come	l’EP	e	la	TVPDI.	L’analisi	dei	risultati	ha	reso	possibile	anche	la	valutazione	delle	terapie	antitrombotiche	utilizzate	per	 il	 trattamento	di	queste	patologie,	sia	in	 termini	di	efficacia	che	di	 sicurezza.	 Inoltre,	una	migliore	conoscenza	del	rischio	 e	 della	 gestione	 dei	 sanguinamenti	 in	 corso	 di	 trattamenti	anticoagulanti,	compresi	i	DOACs,	è	stata	ottenuta	grazie	ad	una	revisione	ed	analisi	 della	 letterattura.	 L’obiettivo	 iniziale	 di	 valutazione	 dell’impatto	 dei	DOACs	nel	TEV	ha	dovuto	 tuttavia	subire	una	significativa	modifica	a	causa	delle	 tempistiche	 di	 approvazione	 ed	 delle	 indicazioni	 e	 regimi	 di	rimborsabilità	 stabiliti	 da	 AIFA.	 Tuttavia,	 i	 risultati	 del	 progetto	 di	 ricerca		hanno	permesso	di	porre	delle	solide	basi	per	valutare	l’impatto	dei	DOACs	in	alcuni	ambiti	specifici	del	TEV	e,	in	particolare,	nella	gestione	dei	pazienti	con	EP	a	basso	rischio	di	complicanze	e	nella	terapia	delle	TVPDI.	Per	 quanto	 riguarda	 la	 stratificazione	 prognostica	 dell’EP	 acuta,	 i	risultati	 dallo	 studio	 LORPELHS	 hanno	 confermato	 la	 validità	 del	 PESI	nell’identificare	 i	 pazienti	 a	 basso	 rischio	 di	 mortalità	 a	 breve	 termine.	 I	risultati	 hanno	 altresì	 evidenziato	 come	 la	 durata	 del	 ricovero	 ospedaliero	per	EP	sia	ancora	piuttosto	lunga	nella	realtà	italiana,	anche	in	caso	di	basso	rischio	 di	 eventi	 avversi,	 specialmente	 se	 confrontata	 con	 le	 indicazioni	 di	linee	guida	internazionali	ed	i	risultati	di	importanti	studi	recenti.	E’	possibile	ipotizzare	che	il	solo	giudizio	clinico	standard	non	sia	in	grado	di	identificare	
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adeguatamente	questi	pazienti	a	basso	rischio	e	che,	pertanto,	l’utilizzo	di	un	semplice	 strumento	 di	 stratificazione	 prognostica,	 come	 il	 PESI,	 possa	portare	 ad	 un	 significativo	 miglioramento	 nella	 loro	 identificazione	 e	gestione.	 Questa	 considerazione	 ha	 portato	 a	 progettare	 lo	 studio	 iAPP	(Impact	 Analysis	 of	 Prognostic	 stratification	 for	 Pulmonary	 embolism),	recentemente	 approvato	 dal	 comitato	 etico	 provinciale	 di	 Varese	 (centro	coordinatore	dello	studio)	ed	in	fase	di	partenza.		I	 risultati	 dello	 studio	LORPELHS	non	hanno	evidenziato	una	 influenza	del	 tipo	 di	 terapia	 anticoagulante	 sulla	 durata	 del	 ricovero	 ospedaliero.	Tuttavia,	 questo	 risultato	 puo’	 essere	 ascritto	 alle	 diverse	 caratteristiche	basali	dei	pazienti	che	sono	stati	trattati	con	eparina+dicumarolico	rispetto	a	quelli	 trattati	 con	 sola	 eparina	 (più	 frequentemente	 oncologici).	 	 E’	ipotizzabile,	infatti,	che	la	risposta	individuale	alla	terapia	dicumarolica,	e	di	conseguenza	 il	 tempo	 per	 raggiungere	 un	 adeguato	 livello	 di	anticoagulazione,	 influenzino	 la	 durata	 del	 ricovero	 ospedaliero.	 In	quest’ottica,	 l’utilizzo	 dei	 DOACs,	 grazie	 alla	 loro	 rapidità	 d’azione	 e	prevedibilità	 farmacocinetica,	 potrebbe	 portare	 di	 per	 sé	 ad	 una	 riduzione	della	 durata	 del	 ricovero,	 indipendentemente	 dalla	 stratificazione	prognostica.	 Per	 tale	 motivo,	 nella	 fase	 di	 intervento	 del	 progetto	 (studio	iAPP)	è	stato	deciso	di	adottare	una	randomizzazione	stratificata	per	la	scelta	del	 farmaco	 anticoagulante	 (DOACs	 versus	 dicumarolico),	 al	 fine	 di	compararne	l’influenza	sulla	durata	di	ricovero.	
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Per	quanto	riguarda	il	trattamento	delle	TVPDI,	lo	studio	retrospettivo	di	coorte	 condotto	 ha	 evidenziato	 una	 incidenza	 di	 recidiva	 di	 TEV	 non	trascurabile	(15%	dei	pazienti,	4.1	per	100	anni-paziente)	e	rappresentata	da	un	evento	maggiore	 in	oltre	 la	metà	dei	 casi.	 Il	 tasso	di	 recidiva	 è	 risultato	significativamente	 più	 alto	 nei	 pazienti	 con	 un	 evento	 indice	 idiopatico	 o	associato	 ad	 una	 neoplasia	 attiva,	 ripetto	 ai	 pazienti	 che	 presentavano	 un	fattore	di	rischio	temporaneo.	Lo	 studio	 ha	 anche	 permesso	 di	 valutare	 un	 approccio	 terapeutico	 più	breve	 (EBPM	 per	 4-6	 settimane,	 utilizzato	 in	 circa	 il	 90%	 dei	 pazienti)	rispetto	 a	 quello	 attualmente	 suggerito	 dalle	 linee	 guida	 internazionali,	seppur	 con	 basso	 grado	 di	 evidenza.	 I	 risultati	 mostrano	 come	 questo	trattamento	anticoagulante	di	breve	durata	possa	essere	sufficiente	per	una	proporzione	sostanziale	di	pazienti,	come	quelli	con	TVPDI	associata	a	fattore	di	 rischio	 temporaneo.	 Al	 contrario,	 un	 trattamento	 anticogulante	 più	prolungato	 sembra	 essere	 necessaro	 in	 sottogruppi	 di	 pazienti	 a	 più	 alto	rischio	di	 recidiva,	 come	 i	pazienti	oncologici	e	quelli	 con	TVPDI	 idiopatica.	Tuttavia,	se	una	durata	di	3	mesi	sia	sufficiente	per	prevenire	 le	recidive	di	TEV	 in	 questi	 sottogruppi	 di	 pazienti,	 rimane	 da	 eseere	 stabilito	 in	 trial	clinici.			Infine,	 per	 quanto	 riguarda	 i	 sanguinamenti	 in	 corso	 di	 terapia	anticogulante,	 la	 revisione	 della	 letteratura	 ha	 portato	 a	 concludere	 che	 i	farmaci	 “convenzionali”	 e	 quelli	 di	 nuova	 generazione	 sono	 associati	 ad	 un	rischio	 clinicamente	 importante	 di	 emorragia	 maggiore,	 intorno	 al	 1-4%	
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all’anno.	E’	pertanto	fondamentale,	in	questi	casi,	mettere	in	atto	strategie	di	rapido	“reversal”	dell’azione	anticoagulante.	Le	misure	generali	di	 supporto	sono	fondamentali	in	caso	di	sanguinamenti	pericolosi	per	la	sopravvivenza,	unitamente	 a	 misure	 specifiche	 per	 antagonizzare	 l’effetto	dell’anticoagulante	coinvolto.	Al	momento,	sono	disponibili	degli	antidoti	per	l’eparina	non	 frazionata	 (solfato	di	 protamina)	 e	per	 i	 farmaci	 dicumarolici	(vitamina	 K).	 Nuovi	 antidoti,	 specificatamente	 indirizzati	 ai	 DOACs,	 sono	attualmente	in	corso	di	sperimentazione	(andexanet,	idarucizumab,	PER977)	e	potrebbero	 fornire	un	 importante	aiuto	nella	gestione	dei	 sanguinamenti,	se	la	loro	efficacia	e	sicurezza	sarà	confermata	dai	trial	clinici.			 			
